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https://doi.org/10.1016/j.celrep.2020.107796SUMMARYNervous tissue homeostasis requires the regulation of microglia activity. Using conditional gene targeting in
mice, we demonstrate that genetic ablation of the small GTPase Rhoa in adult microglia is sufficient to trigger
spontaneous microglia activation, producing a neurological phenotype (including synapse and neuron loss,
impairment of long-term potentiation [LTP], formation of b-amyloid plaques, and memory deficits). Mecha-
nistically, loss of Rhoa in microglia triggers Src activation and Src-mediated tumor necrosis factor (TNF)
production, leading to excitotoxic glutamate secretion. Inhibiting Src in microglia Rhoa-deficient mice atten-
uates microglia dysregulation and the ensuing neurological phenotype. We also find that the Rhoa/Src
signaling pathway is disrupted in microglia of the APP/PS1 mouse model of Alzheimer disease and that
low doses of Ab oligomers trigger microglia neurotoxic polarization through the disruption of Rhoa-to-Src
signaling. Overall, our results indicate that disturbing Rho GTPase signaling in microglia can directly cause
neurodegeneration.INTRODUCTION
Microglia are yolk-sack-derived myeloid cells that populate the
early-developing nervous system (Ginhoux et al., 2010; Kierdorf
et al., 2013; Schulz et al., 2012). Under physiological conditions,
microglia continuously extend and retract their cellular pro-
cesses, monitoring the central nervous system (CNS) paren-
chyma for tissue damage or infections and checking the func-
tional status of brain synapses (Crotti and Ransohoff, 2016).
Although attempts aremade to repair injuries to the parenchyma,
exacerbation or prolonged microglial activation may trigger and/
or accelerate neuronal damage in neurogenerative conditions or
delay CNS recovery after insults (Go´mez-Nicola et al., 2013, RiceThis is an open access article undet al., 2015; Spangenberg et al., 2016). Such a detrimental role
for microglia can be attributed to the loss/disruption of microglia
immune restrain mechanisms (Deczkowska et al., 2018), which
leads to sustained deregulation of their activation and conse-
quent overproduction of proinflammatory cytokines (inter-
leukin-1b [IL-1b] and tumor necrosis factor [TNF]), nitric oxide
(NO), and reactive oxygen species (ROS) and an increased
release of glutamate (Block et al., 2007).
Proinflammatory microglial activation is associated with pro-
found changes in microglia morphology requiring cytoskeleton
reorganization (abd-el-Basset and Fedoroff, 1995; Kaur, 1997).
The GTPases of the Rho family, from which Rhoa, Rac1, and
Cdc42 are the founding members, are key orchestrators ofCell Reports 31, 107796, June 23, 2020 ª 2020 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Rhoa Is Required for Microglia Survival, and Its Ablation Triggers Spontaneous Microglia Activation
(A) Expression of Rhoa in microglia from the brains of Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ mice 35–45 days post-TAM (n = 4 mice).
(B) Confocal images for Iba1 on tissue sections for the indicated brain regions from Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ 35–45 days post-TAM (n = 10–12 mice).
Scale bars: 50 mm.
(C) Flow cytometry analysis of microglial numbers in Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ mice 35–45 days post-TAM (n = 9 mice).
(D), Flow cytometry analysis of cell death markers in microglia from Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ mice 150 days post-TAM (n = 5 mice per condition).
(E) Sholl analysis in microglia from the neocortex of Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ 35–45 days post-TAM (n = 12–13 cells from 3 mice). Scale bar: 20 mm.
(legend continued on next page)
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OPEN ACCESScytoskeleton dynamics (Bustelo et al., 2007) and are therefore
well positioned to govern microglia activation. Typical GTPases
function as binary switches by cycling between a GDP-bound
inactive, ‘‘off’’ state, and a GTP-bound active, ‘‘on’’ state, in
which they can directly interact with downstream effectors to
regulate different cell functions (Hodge and Ridley, 2016). Rho
GTPases play important roles during CNS development, and
dysregulation of their expression and/or activity is associated
with different neurological disorders (Stankiewicz and Linseman,
2014). Indeed, changes in Rhoa activity or in the activities of its
effectors are implicated in several neurodegenerative condi-
tions, including stroke, Alzheimer disease (AD) and Parkinson
disease, and amyotrophic lateral sclerosis (DeGeer and La-
marche-Vane, 2013; Droppelmann et al., 2014). Here, using
tamoxifen (TAM)-inducible conditional gene inactivation in
mice, we investigated the bona fide function of Rhoa inmicroglia.
Our data reveal critical roles for Rhoa signaling in regulating mi-
croglia immune activity and microglia-dependent synaptic
integrity.
RESULTS
Conditional Ablation of Rhoa in Adult Microglia
To study the role of Rhoa in adult microglia, we crossed
Cx3cr1CreER-IRES-EYFP mice (Parkhurst et al., 2013; Goldmann
et al., 2013; Yona et al., 2013) with mice carrying Rhoa condi-
tional alleles (Herzog et al., 2011; Jackson et al., 2011; Fig-
ure S1A). In Cx3cr1CreER mice, the CreER-IRES-EYFP transgene
is transcriptionally active in Iba1+ brain myeloid cells (Goldmann
et al., 2016; Figure S1B) and microglia (Figure S1C). As
expected, following TAM administration, Cre-mediated
recombination substantially decreased Rhoa expression in
Rhoafl/fl:Cx3cr1CreER+ microglia (Figures 1A and S1D). Because
Rhoafl/fl:Cx3cr1CreER+ mice have only one intact copy of
Cx3cr1 and decreasedCx3cr1 protein levels could per se disrupt
microglia homeostasis and be a confounding factor affecting the
conclusions of our study, we confirmed that the number of mi-
croglia expressing Cx3cr1 as well as microglial number did not
vary significantly betweenRhoafl/fl andCx3cr1CreER+(FigureS1E).
We also included other controls to further validate our experi-
mental set up (Figures S1F–S1H).
Rhoa Is Required for Microglial Survival and Activation
We then evaluated the requirement of Rhoa for microglia homeo-
stasis. We observed a decrease in the number of Iba1+ cells in
the neocortex, hippocampus, and striatum comparing Rhoafl/fl
with Rhoafl/fl:Cx3cr1CreER+ littermates (Figure 1B). Using flow cy-
tometry, we confirmed a decrease in the numbers of microglia in
Rhoafl/fl:Cx3cr1CreER+ brains (Figure 1C). Such a decrease in mi-
croglial numbers persisted in the brains of mature adult
Rhoafl/fl:Cx3cr1CreER+mice (Figure S2A). The decrease onmicro-
glial numbers following Rhoa ablation could be caused by(F) qRT-PCR in microglia sorted from brains of Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER
(G) TNF amounts (ELISA) in Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ brains 35–45 days
Data are represented asmeanwith 95%confidence interval (CI). *p < 0.05 (Mann-W
S3.increased microglial cell death. Indeed, we found increased ne-
crosis (Zombie+Anv) in Rhoafl/fl:Cx3cr1CreER+ microglia (Fig-
ure 1D). However, microglial numbers in Rhoafl/fl:Cx3cr1CreER+
mice 40 days post-TAM (Figure 1C) and 150 days post-TAM (Fig-
ure S2A) were comparable. This suggested that proliferation
could be counterbalancing cell death to stabilize microglial
numbers. Accordingly, we found increased microglial prolifera-
tion in mature Rhoafl/fl:Cx3cr1CreER+ mice compared with
Rhoafl/fl littermates (Figure S2B).
Changes in microglial cell morphology are usually concurrent
with alterations in microglial function. Morphological analysis re-
vealed that Rhoa mutant microglia were less ramified than
Rhoafl/fl microglia (Figures 1E and S2C). Modifications in actin
cytoskeleton organization and dynamics most likely underlie
the changes found inmicroglia morphology. Inhibiting Rhoa acti-
vation in microglial cultures by expressing a dominant-negative
Rhoa mutant (RhoaT19N; Figure S2D), resulted in a loss of actin
stress fibers (Figure S2E) and decreased the speed of microglia
protrusion extension, which is regulated by actin dynamics
(Figure S2F).
Next, we evaluated whether the production of inflammatory
cytokines was increased in Rhoafl/fl:Cx3cr1CreER+ microglia.
Indeed, Rhoa mutant microglia contained greater amounts of
mRNA transcripts coding for the classical proinflammatory cyto-
kines TNF and IL-1b, but not for IL-6 (Figure 1F). The increased
production of TNF in Rhoa mutant microglia resulted in
increased TNF amounts in Rhoafl/fl:Cx3cr1CreER+ brains
(Figure 1G).
In addition to microglia, long-lived nonparenchymal macro-
phages residing on brain interfaces are potentially targeted in
Cx3cr1CreER+ mice (Goldmann et al., 2016). However, and in
contrast to microglia, Rhoa expression in brain macrophages
(CD11b+CD45high cells; gated as shown in Figure S2G) as well
as their numbers, viability, and reactivity were comparable be-
tween Rhoafl/fl:Cx3cr1CreER+ mice and aged-matched Rhoafl/fl
littermates (Figures S2G and S2H). Because Cx3cr1 is also ex-
pressed on peripheral organs (Jung et al., 2000), some degree
of Cre-mediated recombination was expected to occur outside
the CNS of Rhoafl/fl:Cx3cr1CreER+ mice (Parkhurst et al., 2013).
However, blood monocytes and spleen macrophages (Fig-
ure S2I) showed a similar abundance of Rhoa mRNA transcripts
between Rhoafl/fl:Cx3cr1CreER+ mice and Rhoafl/fl littermates
(Figure S2J). The percentage of different CD45+ myeloid popula-
tions was also comparable between the genotypes (Figures S2K
and S2L), indicating that the Rhoamutant phenotype relates pre-
dominantly to microglia and not to macrophages.
To further establish that the loss of Rhoa in microglia would be
sufficient to trigger their activation spontaneously in a cell auton-
omous manner, we depleted Rhoa in different cell culture exper-
imental setups and evaluatedmicroglia activation. We found that
(1) loss of Rhoa in primary cortical microglial cultures obtained
from Rhoa floxed mice (Figure S3A) led to an increased+ mice 35–45 days post-TAM (n = 4 mice).
post-TAM (n = 8–11 mice).
hitney test in A, C, D, F, andG; 2-way ANOVA in B and E). See also Figures S1–
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Figure 2. Rhoa Deficiency in Adult Microglia Leads to Phenotypic Features Underlying Neurological Disorders
(A) Primary cortical microglial cultures expressing FLIPE600nSurface were transduced with lentiviruses coding pLKO or Rhoa shRNA (CT; n = 11–15 cells from 3
cultures).
(B) Extracellular glutamate in the culture media of pLKO and Rhoa KD primary cortical microglia cultures (n = 4 cultures). faus, fluorescence arbitrary units.
(legend continued on next page)
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OPEN ACCESSexpression and secretion of TNF (Figures S3B andS3C), and that
(2) knocking down Rhoa in microglial cell lines (Figure S3D) also
increased TNF expression (Figure S3E) and secretion (Fig-
ure S3F), (3) increased nuclear factor kB (NF-kB) activation (Fig-
ures S3G and S3H), and (4) led to the degradation of the inhibitor
of kB (Figure S3I; Shcherbakova et al., 2016).
Ablation of Rhoa in Microglia Leads to a Neurological
Phenotype
Increased secretion of TNF by microglia can be detrimental to
neurons because TNF autocrinally increases the release of gluta-
mate (Takeuchi et al., 2006), thus causing excitotoxic damage to
neurites and neurons (Maezawa and Jin, 2010). Using the gluta-
mate release FRET biosensor FLIPE600nSurface, which specif-
ically discriminates glutamate release over its uptake or its intra-
cellular mobilization via cell metabolism (Okumoto et al., 2005),
we showed that Rhoa knockdown (KD) increased glutamate
release from living primary cortical microglia (Figure 2A). This
increased release led to an accumulation of glutamate in the
extracellular space (Figure 2B). Incubation of primary hippocam-
pal neurons with microglia conditioned media (MCM) collected
from primary cortical microglia knocked down for Rhoa
increased neurite beading (Figure 2C), a characteristic of
glutamate excitotoxicity (Maezawa and Jin, 2010). Confirming
that microglia-secreted glutamate was driving neurite damage,
pharmacological inhibition of the NMDA-type of glutamate re-
ceptors on hippocampal neurons abrogated the neurite beading
effect of Rhoa KD MCM (Figure 2C).
We then evaluated the impact of microglia-dependent neuro-
toxicity in Rhoafl/fl:Cx3cr1CreER+ mice. Here, we focused our an-
alyses primarily on the hippocampus because this brain region is
vulnerable to TNF-induced glutamate excitotoxicity (Yu et al.,
2002). We found less excitatory synaptic puncta in
Rhoafl/fl:Cx3cr1CreER+ hippocampus (evaluated by the number
of vGlut-1+/PDS-95+ colocalization puncta) than that in Rhoafl/fl
littermates (Figure 2D). The amounts of vGlut-1 protein were
comparable, whereas the amounts of PSD-95 were significantly
reduced in the Rhoafl/fl:Cx3cr1CreER+ hippocampus (Figure 2E).
Because synapse loss can adversely affect neuronal plasticity,
we assessed the long-term potentiation (LTP) of hippocampal(C) Primary hippocampal neuronal cultures expressing mVenus were incubated fo
fromWTmice that were previously infectedwith pLKO or Rhoa shRNA lentiviruses
NMDA receptor antagonist kynurenic acid (KyA; 1 mM). Arrowheads display a be
(D) vGlut-1 (green) and PSD-95 (red) immunolabeling on hippocampus CA1 region
Scale bars: 5 mm and 1 mm (high mag). White asterisks denote synaptic puncta.
(E) Western blot for PSD-95 and vGlut-1 on brains lysates from Rhoafl/fl and Rh
loading control.
(F andG) The averaged time course changes in field excitatory post-synaptic poten
mice) and Rhoafl/fl:Cx3cr1CreER+ (n = 9 slices from 5 mice) 35–45 days post-TAM (
to slopes averaged and recorded for 10 min before q-burst stimulation ([0.99 ±
abscissa represents the time that average begun. Experiments are the average of
before (1 or 3) and 58–60min after (2 or 4) q-burst stimulation and is composed by
Themagnitude of LTP obtained in slices from each genotype; the values in ordinat
normalized to pre q-burst values.
(H) Confocal images of hippocampi from Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ 35–
100 mm.
(I) Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ were evaluated in the NOR test (after a 4-h
Data are represented as mean with 95% CI. *p < 0.05 (Mann-Whitney test in A, Bsynapses in Rhoafl/fl:Cx3cr1CreER+ animals. A q-burst stimulation
of hippocampal slices from Rhoafl/fl mice led to an initial
enhancement of field excitatory post-synaptic potential (fEPSP)
slope followed by a decrease and stabilization period, but at the
end of recording period, fEPSP slope values remained higher
than before the q-burst stimulation (Figure 2F, blue circles). In
Rhoafl/fl:Cx3cr1CreER+ slices, however, the same q-burst stimula-
tion caused only an initial transient increase in fEPSP slope
values (Figure 2F, red circles), which decreased progressively to-
ward pre-q-burst levels. LTP magnitude was significantly lower
on hippocampal slices from Rhoafl/fl:Cx3cr1CreER+ mice (Fig-
ure 2G), indicating a marked LTP impairment.
Changes in synapse number/function may be associated with
neuronal cell death (Palop et al., 2006). Indeed, we found an in-
crease in TUNEL+ cells in the Rhoafl/fl:Cx3cr1CreER+ hippocam-
pus (Figure 2H), indicating neuronal apoptosis. In line with this,
Rhoafl/fl:Cx3cr1CreER+ hippocampi contained less NeuN-positive
neurons than hippocampi from Rhoafl/fl littermates (Figure 2H).
Synapse loss and LTP impairment can result in behavioral def-
icits. To address this possibility, we compared the performance of
Rhoafl/fl:Cx3cr1CreER+andRhoafl/flmice indifferentbehavioralpar-
adigms, including elevated plus-maze (EPM) to evaluate anxiety-
like behavior, open field (OF) to test general activity levels and
gross motor function, and novel object recognition (NOR) to test
recognition memory. Both EPM (Figure S3J) and OF (Figures
S3K–S3P) tests did not show significant differences between ge-
notypes. In the NOR test, however, Rhoafl/fl:Cx3cr1CreER+ mice
spent less time exploring the novel object (Figure 2I) and their ca-
pacity to discriminate the novel object over the familiar object was
reduced, indicating deficits in recognition memory (Figure 2I).
Given thatRhoa, Rhob, andRhocshare highdegreeof similarity
(Wheeler and Ridley, 2004), we asked whether depleting Rhob or
Rhoc would also lead to spontaneous microglial activation. Con-
trasting to Rhoa KD, the KD of Rhob or Rhoc (validations in Fig-
ure S4A) did not alter microglia morphology (Figure S4B), ROS
production (Figure S4C), glutamate release (Figure S4D), NF-kB
nuclear translocation (Figure S4E), or TNF release (Figure S4F).
Furthermore, CM from Rhob KD or Rhoc KD microglial cultures
did not induce neurite beading on hippocampal neurons (Fig-
ure S4G). To check whether a compensatory Rhoc upregulationr 24 h with conditioned media from primary microglial cultures (MCM) obtained
(n = 3–4 cultures). Under some conditions, neuronswere co-incubatedwith the
aded neurite. Scale bar: 50 mm.
of Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ mice 35–45 days post-TAM (n = 7 mice).
oafl/fl:Cx3cr1CreER+ mice 35–45 days post-TAM (n = 6 mice). GAPDH was the
tial (fEPSP) slope induced by q-burst stimulation in Rhoafl/fl (n = 11 slices from 6
F). Ordinates represent normalized fEPSP slopes, from which 0% corresponds
0.04 mV/ms (Rhoaflfl], 0.93 ± 0.04 mV/ms [Rhoafl/fl:Cx3cr1CreER+]), and the
six consecutive responses obtained for Rhoafl/fl or Rhoafl/fl:Cx3cr1CreER+ mice
the stimulus artifact, followed by the pre-synaptic fiber volley and the fEPSP. (G)
es represent the average of the fEPSP recorded 50–60 min after LTP induction,
45 days post-TAM (n = 8 mice for TUNEL; n = 6 mice for NeuN). Scale bars:
delay) 35–45 days post-TAM (n = 9 mice).
, and D–I; Kruskal-Wallis test in C). See also Figures S3 and S4.
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measured Rhoc activity in living Rhoa KDmicroglia and detected
no overt difference in basal Rhoc activation (Figure S4H).
Rhoa Restrains Src Tyrosine Kinase Activity in Microglia
We next investigated the signaling pathway downstream of Rhoa
controlling microglial activation. Csk, the endogenous repressor
of Src family of tyrosine kinases (Nada et al., 1991), plays key roles
in inflammation (Thomas et al., 2004). Besides, Src, the prototype
and founding SFK (Src family kinase) member, is a key regulator
of microglia activation (Socodato et al., 2015b). Therefore, Csk/
Srcemergedasgoodcandidates forcontrollingmicroglial function,
and we hypothesized that Rhoa might modulate microglia activa-
tion by this pathway.
To test this hypothesis, we investigated whether Rhoa defi-
ciency increased Src activity in microglia. Rhoafl/fl:Cx3cr1CreER+
microglia containedgreater amounts of activeSrc thancontrolmi-
croglia (Figure 3A). Src activity was also increased in Rhoa KD N9
microglia and in Rhoa KD CHME3 microglia (Figures 3B and 3C).
To further demonstrate that Src activity is directly linked to Rhoa
function, we used the pSicoR vector (Ventura et al., 2004). In the
pSicoR vector system, Cre expression causes recombination
and excision of both short hairpin RNA (shRNA) and EGFP se-
quences, turning their expression off (Figure 3D). We found that
activation of Src did not change by expressing a scrambled
shRNA sequence in lenti-CT microglia or in lenti-Cre microglia
(Figure 3E), but significantly increasedby expressing short-hairpin
Rhoa (shRhoa) sequences in lenti-CT microglia (Figure 3E). Con-
firming the Rhoa-dependent Src modulation, expressing shRhoa
in lenti-Cre microglia excised shRhoa sequences and Src activa-
tion was retained to control levels (Figure 3E).
Csk is the endogenous repressor of Src, and we observed a
decrease of Csk mRNA transcripts in Rhoafl/fl:Cx3cr1CreER+ mi-
croglia (Figure 3F) and of Csk protein amounts in Rhoa KDN9mi-Figure 3. Loss of Rhoa in Adult Microglia Leads to Src Hyperactivation
(A) Western blot for Src pTyr416 on lysates frommagnetic-activated cell sorting (MA
post-TAM (n = 4 mice). Src was the loading control.
(B) Western blot for Src pTyr416 on lysates from control (CT) or Rhoa shRNA (Rho
control.
(C) CHME3microglial cultures expressing the Src FRET biosensor (KRas Src YPet
cultures). Pseudocolor ramps represent min/max CFP/FRET ratios. Scale bar: 5
(D) Schematic representation of pSicoR vector-dependent knockdown of Rhoa
dependent recombination of loxP sites.
(E) Western blots for Src pTyr416 on lysates from CHME3microglial cells transduc
lox) or Rhoa shRNA (lox-shRhoa-lox) (n = 4 cultures). Under some conditions, cel
expressing vector (lenti-Cre). Src was the loading control.
(F) qRT-PCR on sorted brain microglia from of Cx3cr1CreER+ and Rhoafl/fl:Cx3cr1
(G) Western blot for Csk on lysates from control (CT) or Rhoa shRNA (Rhoa KD) sta
(H)Western blot for Csk or Src pTyr416 on lysates fromCHME3microglial cells tran
cultures).
(I) Schematic representation of Rhoa activation using chemical-inducible dimeriz
(J)Western blot for Src pTyr416 on lysates frompLKOor Csk shRNA stable CHME3
co-transfected with YFP-FKBP and Lyn11-FRB (CT-CID) or with YFP-FKBP-Rho
mycin for 24 h. Src was the loading control.
(K) Confocal imaging of p65-GFP-transfected (green) pLKO, Csk KD, or SrcY527F s
stained with DAPI (blue). Scale bar: 10 mm.
(L) TNF amounts (ELISA) were in the culture supernatant of pLKO (CT), Csk KD o
Data are represented asmean with 95%CI. *p < 0.05 (Mann-Whitney test in A, B, C
Figure S4.croglia (Figure 3G). To further link Rhoa activity with the regula-
tion of Csk expression, we forced Rhoa activation by
expressing the constitutively active Rhoamutant RhoaQ63L in mi-
croglia. CHME3 microglia expressing RhoaQ63L had greater
amounts of Csk and, consequently, lesser amounts of active
Src (Figures 3H, S4I, and S4J), suggesting that Rhoa is an up-
stream regulator of the Csk/Src pathway in microglia.
To strengthen the link between Rhoa activity, Csk expression,
and Src activity in microglia, we tested whether depleting Csk
while activating Rhoa would result in Src activation. We forced
Rhoa activation using a RhoGTPase chemical inducible dimeriza-
tion (CID) strategy (Figure 3I; Inoue et al., 2005). In this experi-
mental set-up, the FK506 binding protein (FKBP) and rapamycin
binding domain of mTOR (FRB) is fused to the membrane-target-
ing sequence of Lyn (Lyn11-FRB) to provide a plasma membrane
anchor for the constitutively active form of Rhoa (Rhoa CA), which
is expressed as a cytosolic fusion with FKBP and YFP. When mi-
croglia expressing both constructs are exposed to rapamycin,
YFP-FKBP-Rhoa (CA) rapidly translocates to the plasma mem-
brane and binds to Lyn11-FRB, triggering fast activation of Rhoa
(Inoue et al., 2005; Figure 3I). Indeed, following exposure to rapa-
mycin, Src activationdecreased inpLKOCHME3microglia co-ex-
pressing Lyn11-FRB and YFP-FKBP-Rhoa (CA) (Rhoa-CID) rela-
tive to microglia co-expressing Lyn11-FRB and YFP-FKBP (CT-
CID) (Figure 3J). However, in Csk-depleted microglia (Csk KD;
validation in Figure S4K), triggering activation of Rhoa (Rhoa-
CID) failed to decrease Src activation (Figure 3J).
Lastly, we examined whether forcing Csk downregulation or
Src hyperactivation would be sufficient to activate microglia.
Csk KD, which caused a large increase in Src activation (Fig-
ure S4L), or expressing the constitutively active Src mutant
SrcY527F (Figure S4L; with additional control in Figure S4M) led
to NF-kB activation (Figure 3K) and increased TNF secretion
(Figure 3L) in CHME3 microglia.through Csk
CS)-separatedmicroglia fromRhoafl/fl and Rhoafl/fl:Cx3cr1CreER+mice 90 days
a KD) stable N9 microglial cell sub-clones (n = 4 cultures). Src was the loading
) were transducedwith pLKO or Rhoa shRNA lentiviruses(n = 15–19 cells from 3
mm.
(active pSicoR). Rhoa re-expression (inactive pSicoR) is achieved after Cre-
ed with lentiviruses carrying pSicoR with a scrambled sequence (lox-scramble-
ls were transfected with an empty vector (lenti-CT) or with a Cre recombinase-
CreER+ 35–45 days post-TAM (n = 3-4 mice).
ble N9microglial cell sub-clones (n = 4 cultures). Actin was the loading control.
sfectedwith the RhoaQ63Lmutant. Actin and Srcwere the loading controls (n = 4
ation (CID).
microglial cell sub-clones (n = 3–5 cultures). Under some conditions, cells were
a (CA) and Lyn11-FRB (Rhoa-CID). All groups were treated with 500 nM rapa-
table N9microglial cell sub-clones (n = 29–30 cells from 3 cultures). Nuclei were
r SrcY527F stable N9 microglial cell sub-clones (n = 6 cultures).
, F, G, and H; two-way ANOVA in E and I; one-way ANOVA in K and L). See also
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Neurodegeneration
Next, we investigated whether blocking Src would rescue, to
some extent, synaptotoxicity and the associated memory defi-
cits in Rhoafl/fl:Cx3cr1CreER+ mice. Therefore, following TAM
administration, we injected Rhoafl/fl:Cx3cr1CreER+ mice weekly
with the potent Src blocker AZD 0530 (Figure 4A) and 1 month
later confirmed that this regimen of AZD 0530 was effective in
decreasing Src activation in their brain (Figure 4B). A single intra-
peritoneal (i.p.) injection of AZD 0530 was sufficient to reduce
Src activation in the brains of naive wild-type (WT) mice (Fig-
ure S5A) with an apparent IC50 of approximately 0.024 mg/kg
(Figure S5B), indicating that the amounts of AZD 0530 present
in the brain after 1 week are sufficient to sustain Src inhibition.
Src inhibition by AZD 0530 prevented the decrease of microglial
numbers in Rhoafl/fl:Cx3cr1CreER+ mice (Figures 4C and 4D; Fig-
ures S5C and S5D) and the increase of mRNA transcript, of TNF
in Rhoafl/fl:Cx3cr1CreER+ brains (Figure 4E).
Expressing the dominant-negative Src mutant SrcY416F in
Rhoa KD microglia prevented TNF release compared with
Rhoa KD microglia (Figure 4F). SrcY416F expression also caused
a reduced activation of NF-kB in Rhoa KDmicroglia (Figure S5E).
Pharmacological inhibition of Src, using the Src blocker SKI-1, inFigure 4. Src Inhibition Compensates Rhoa Deficiency in Microglia, Pr
(A) Regimen of 10 mg/kg AZD 0530 or DMSO injections to Rhoafl/fl:Cx3cr1CreER+
(B) Western blot for Src pTyr416 on lysates from the brains of Rhoafl/fl:Cx3cr1CreER+
the loading control.
(C) Fluorescence-activated cell sorting (FACS) analysis of microglia in Rhoafl/fl and
mice).
(D) Iba1 immunolabeling on tissue sections from the hippocampal dentate gyrus
DMSO (n = 6–7 mice).
(E) qRT-PCR from the neocortex of Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ mice injec
(F) TNF amounts (ELISA) in the culture supernatant of pLKO (CT), Rhoa KD or Rho
microglial cell sub-clones (n = 3–10 cultures).
(G) Primary microglia from WT or TNF KO mice were infected with pLKO (CT) an
biosensor FLIPE (n = 11–32 cells from 3 cultures).
(H) CHME3microglia (n = 6 cells from 2 independent cultures), N9microglia (n = 6 c
the glutamate release FRET biosensor FLIPE were treated with different concentr
(I) CHME3 microglial cells were co-transfected with the RhoaWT or RhoaT19N and
Cultures were then incubatedwith an FcR blocking solution for 10min, and under
ml; 48 h).
(J) pLKO (CT), Rhoa KD, Csk KD, or SrcY527F CHME3microglial cell sub-clones we
from 3 cultures). Under some conditions, Rhoa KD cells were treated with the Sr
(POM; 500 nM; 24 h), recombinant TNF (30 pg/ml; 24 h), or the gap junction bloc
(K) CHME3microglial cells expressing the glutamate release FRET biosensor FLIP
FRB-mCherry (n = 8–10 cells from 3 cultures) and treated with 500 nM rapamyc
(L) Glutamate amounts in the culture media from pLKO (CT), Rhoa KD, Csk KD,
ditions, Rhoa KD cells were treated with the Src inhibitor SKI-1 (500 nM; 24 h).
(M) Primary hippocampal neuronal cultures expressing mVenus were incubated
(infected with CT or Rhoa KD lentiviruses) or TNF KO mice (infected with Rhoa K
(N) Primary hippocampal neuronal cultures expressing mVenus were incubated fo
N9 microglial cell sub-clones (n = 3–7 cultures). Under some conditions, Rhoa
Recombinant TNF (30 pg/ml; 24 h) was used in CT microglial clones.
(O) vGlut-1 (green) and PSD-95 (red) immunolabelling in primary hippocampal neu
(MCM) overexpressing RhoaWT, RhoaT19N, or SrcY416F (n = 20 neurites from 2 cu
solution for 20 min and in some treated with adalimumab (anti-TNF; 5 mg/ml; 48
(P) vGlut-1 (green) and PSD-95 (red) immunolabeling on tissue sections from the h
10 mg/kg AZD 0530 or DMSO (n = 6-7 mice). Scale bar: 5 mm. Asterisks denote
(Q) DMSO- and AZD 0530-injected Rhoafl/fl or Rhoafl/fl:Cx3cr1CreER+ mice were e
Data are represented as mean with 95% CI. *p < 0.05 (Mann-Whitney test in B; K
Figure S5.CskKDmicroglia also prevented TNF release (Figure 4F) andNF-
kB nuclear translocation (Figure S5E).
Because blocking Src activity in microglia lacking Rhoa abro-
gated TNF production, we postulated that it would also inhibit
glutamate release, thereby preventing microglia from becoming
neurotoxic. Ablating microglial TNF (using TNF knockout [KO])
abrogated the release of glutamate triggered by depleting Rhoa
(Figure 4G), and TNF dose-dependently increased the release of
glutamate from CHME3 microglia, N9 microglia, and primary mi-
croglia (Figure 4H). We further confirmed that TNF released from
microglia was inducing the release of glutamate by using adalimu-
mab (a monoclonal anti-TNF blocking antibody), which blocked
the release of glutamate triggered by overexpressing RhoaT19N
in microglia (Figure 4I). The Src inhibitor SKI-1 attenuated the
release of glutamate in Rhoa KD microglia (Figure 4J), whereas
exogenous application of TNF rescued the release of glutamate
after inhibiting Src in Rhoa KD microglia (Figure 4J). Preventing
TNF production in Rhoa KD microglia, using the antineoplastic
TNF inhibitor pomalidomide (POM), also inhibited the increase
of glutamate release (Figure 4J), which could again be rescued
by exogenous application of TNF (Figure 4J).
Onemain route for glutamate release from activemicroglia is its
extrusion through gap junction hemichannels (Maezawa and Jin,eventing Synapse Loss and Memory Deficits
mice after TAM administration.
mice injected with 10 mg/kg AZD 0530 or DMSO (n = 6mice). Src was used as
Rhoafl/fl:Cx3cr1CreER+mice injected with 10mg/kg AZD 0530 or DMSO (n = 5-7
of Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ mice injected with 10 mg/kg AZD 0530 or
ted with 10 mg/kg AZD 0530 or DMSO (n = 6–9 mice).
a KD:SrcY416F, Csk KD, or Csk KD treated with SKI-1 (500 nM; 24 h) stable N9
d Rhoa KD lentiviruses and then transfected with the glutamate release FRET
ells from 2 cultures), or primarymicroglia (n = 4 cells from 2 cultures) expressing
ations of recombinant TNF. Traced lines represent baseline glutamate release.
the glutamate release FRET biosensor FLIPE (n = 15-20 cells from 2 cultures).
some conditions, RhoaT19N cells were treated with adalimumab (anti-TNF; 5 mg/
re transfected with the glutamate release FRET biosensor FLIPE (n = 7–23 cells
c inhibitor SKI-1 (500 nM; 24 h), the inhibitor of TNF production pomalidomide
ker 18-alpha- glycyrrhetinic acid (10 mM; 24 h).
E were co-transfected with pLKO (CT) or RhoaQ63L together with RapR-Src and
in for 90 min.
or SrcY527F N9 microglial cell sub-clones (n = 4–7 cultures). Under some con-
for 24 h with MCM obtained from primary microglia cultures from WT mice
D lentiviruses) (n = 3 cultures).
r 24 h with MCM obtained from pLKO (CT), Rhoa KD, and RhoA KD + SrcY416F
KD microglia were treated with SKI-1 (500 nM; 24 h) or POM (500 nM; 24 h).
rons incubated for 24 hwith conditionedmedia fromCHME3microglial cultures
ltures). Microglial cultures were pre-incubated with an FcR receptor blocking
h). Scale bar: 5 mm.
ippocampal CA1 region of Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+mice injectedwith
synaptic puncta (yellow).
valuated in the NOR test (n = 10-11 mice).
ruskal-Wallis test in C–E and P; one-way ANOVA in F, G, I–O, and Q). See also
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alpha-glycyrrhetinic acid in Rhoa KD microglia prevented gluta-
mate release (Figure 4J). In addition, hyperactivating Src (by Csk
KD or by expressing SrcY527F) recapitulated the effect of Rhoa
KD in microglia and increased glutamate release (Figure 4J).
Increasing basal Rhoa activation in microglia by expressing
RhoaQ63L was sufficient to decrease glutamate release (Fig-
ure 4K). Therefore, we hypothesized that if Src acted down-
stream of Rhoa to promote glutamate release, then forcing Src
activation, which increases TNF production, in RhoaQ63L-ex-
pressing microglia should result in glutamate release. To test
this hypothesis, we used a Src-CID strategy to exert precise
temporal control over Src activation (Karginov et al., 2010).
Exposing microglial cultures co-expressing RapR-Src and
FRB-mCherry (Src-CID) to rapamycin led to a significant in-
crease in glutamate release (Figure 4K) and resulted in the
release of glutamate in cells expressing RhoaQ63L (Figure 4K).
Rhoa KD or direct Src hyperactivation led to an accumulation
of glutamate in the extracellular medium (Figure 4L). Inhibiting
Src with SKI-1 in Rhoa KDmicroglia also abrogated the extracel-
lular accumulation of glutamate (Figure 4L).
Weassessedwhether inhibitingSrc or TNF after depletingRhoa
would attenuate neurite damage in hippocampal neurons. CM
from TNF-deficient microglia prevented neurite beading caused
by Rhoa KD (Figures 4M and S5F). Inhibiting Src in microglia (us-
ing SKI-1 or the dominant-negative Src mutant SrcY416F) pre-
vented neurite beading in cultured hippocampal neurons caused
by the CM of Rhoa KD microglia (Figures 4N and S5G). CM
from Rhoa KD microglia, in which TNF was inhibited with POM,
also prevented neurite beading, and adding recombinant TNF to
Rhoa KD microglia in the presence of POM induced neurite
beading (Figures 4N and S5G). The CM of control microglia
treated with TNF also led to extensive neurite beading (Figures
4N and S5G). Paralleling the effect in neurite damage, the CM
from microglia overexpressing RhoaT19N produced a significant
loss of synaptic puncta in primary hippocampal neurons (Fig-
ure 4O), and decreasing microglial Src activity or blocking micro-
glial TNF significantly attenuated this effect (Figure 4O). Accord-
ingly, Rhoafl/fl:Cx3cr1CreER+ mice injected with AZD 0530 not
only containedmore hippocampal excitatory synapses (Figure 4P)
but also had increased amounts of the structural synapticmarkers
synapsin-1, synaptophysin, and PSD-95 compared with
Rhoafl/fl:Cx3cr1CreER+ mice injected with vehicle (Figure S5H).
Next, we evaluated, using the NOR test, whether AZD 0530
would also attenuate memory deficits after Rhoa ablation in mi-
croglia. Rhoafl/fl:Cx3cr1CreER+ mice injected with AZD 0530 spent
more time exploring the novel object (Figure 4Q) and discrimi-
nated the novel object better than Rhoafl/fl:Cx3cr1CreER+ mice
injected with vehicle (Figure S5I). We observed no differences in
total object exploration time between Rhoafl/fl:Cx3cr1CreER+
mice injected with AZD 0530 and controls (Figure S5J).
We did not find significant differences between DMSO-in-
jected Cx3cr1CreER+, AZD-injected Cx3cr1CreER+, or Rhoafl/fl
mice in microglial numbers (Figure S5K), excitatory synapse
number (Figure S5L), recognition memory (Figures S5M and
S5N), anxiety-related behavior (Figures S5O–S5S), and locomo-
tor activity (Figure S5T), suggesting that AZD administration did
not affect these features at the steady state.10 Cell Reports 31, 107796, June 23, 2020We also injected Rhoafl/fl:Cx3cr1CreER+ and control
Cx3cr1CreER+ mice with POM (50 mg/kg i.p. 3 times per week
over 4 weeks) and found that this dosage of POM decreased
the expression of TNF in the brains of Cx3cr1CreER+ and
Rhoafl/fl:Cx3cr1CreER+ mice (Figure S5U). Besides decreasing
brain TNF expression, POM administration also significantly pre-
vented the decrease of vGlut-1+/PSD95+ synapses in
Rhoafl/fl:Cx3cr1CreER+ mice (Figure S5V), suggesting that the
increased TNF expression was, at least in part, involved in the
synapse loss elicited by the ablation of Rhoa in microglia.
Rhoa Ablation in Microglia Produces an Amyloid-like
Pathology
Together with synapse loss, LTP impairment, and memory defi-
cits (Figure 2), deposition of amyloid beta (Ab) underlies multiple
CNS neurodegenerative states, including AD. Ablation of Rhoa in
microglia resulted in increased amounts of Ab (Figure 5A) and its
amyloidogenic precursor b-CTF (a carboxyl-terminal fragment
generated by the cleavage of APP (amyloid precursor protein)
by b-secretases; Figure 5B) in Rhoafl/fl:Cx3cr1CreER+ brains. To-
tal APP levels were comparable between genotypes (Figure 5B).
Corroborating the increased amyloidogenic processing of APP,
we detected increased amounts of Ab1-40 peptide and of
Ab1-42 peptide in Rhoa
fl/fl:Cx3cr1CreER+ brains (Figure 5C). We
also found that the excess of Ab formed fibrillar plaque-like
structures (labeled by methoxy-X04) in the neocortex of
Rhoafl/fl:Cx3cr1CreER+ mice but not in Rhoafl/fl neocortices
(Figure 5D).
Production of Ab by neurons is in large part activity dependent
(Cirrito et al., 2005) and induced by the activation of glutamate
receptors (Lesne´ et al., 2005). As decreasing Rhoa activity in mi-
croglia enhanced glutamate secretion, we investigated whether
this increase modulated the production of Ab by neurons. The
CM from microglia overexpressing the dominant-negative
Rhoa mutant RhoaT19N induced a significant increase of Ab42
in primary hippocampal neurons (Figure 5E). This effect was
abrogated by decreasingmicroglial Src activity or by neutralizing
microglial TNF (Figure 5E).
Ab Oligomers Induce Microglia Neurotoxic Polarization
by Decreasing Rhoa Activity
Our results in Rhoafl/fl:Cx3cr1CreER+ mice suggest that microglia
dysregulation drives amyloidogenic processing of APP, leading
to an increased production of Ab by neurons, but could Ab signal
back to microglia and alter Rhoa activity? Using APP/PS1 mice
(Borchelt et al., 1997), in which Ab is abundantly produced and
secretedbyneurons,we foundasignificantdecreaseofRhoaacti-
vation (GTP-Rhoa) and of Csk expression and an increase of Src
activation in APP/PS1 microglia (Figure 5F). No significant differ-
enceswere found in thenumbersofmicroglia,brainmacrophages,
andbloodmonocytes (FiguresS6AandS6B)or in thepercentages
of brain macrophages and blood monocytes expressing GTP-
Rhoa, Csk, or Src Tyr416 phosphorylation (Figures S6C and S6D)
between 4-month-old APP/PS1 and WT littermates.
Next, we investigated whether application of little amounts
(200 nM) of Ab1-42 oligomers could indeed modulate Rhoa
signaling in microglia. We found by FRET, using the Raichu-
Rhoa biosensor (Yoshizaki et al., 2003), that Rhoa activity in
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mers (Figure 5G). Conversely, Src activity at the plasma mem-
brane (visualized by FRET with the KRas Src YPet biosensor)
increased (Figure 5H), and expression of the constitutively active
Rhoa mutant RhoaQ63L significantly attenuated this effect
(Figure 5H).
Using the pIkBa-miRFP703 biosensor to detect the activation
of canonical NF-kBpathway (Shcherbakova et al., 2016), we also
observed that exposure to Ab1-42 oligomers induced time-
dependent activation of the NF-kB pathway in living microglia
(Figure 5I) and overexpressing RhoaQ63L or blocking Src with
AZD 0530 abrogated this effect (Figure 5I). Finally, using the
FLIPE biosensor, we observed by FRET that exposure to
Ab1-42 oligomers increased glutamate release from living micro-
glia in a time-dependent manner (Figure 5J), an effect inhibited
by RhoaQ63L, by AZD 0530, and by neutralizing TNF with adali-
mumab (Figure 5J). These data suggest that Ab oligomers can
signal back tomicroglia and decrease Rhoa activation, providing
a positive feedback loop for Src hyperactivation and TNF-
dependent glutamate release.Blocking Src Decreases Amyloid-like Pathology in
Microglia Rhoa-Deficient Mice
Next, we investigated if inhibiting Src would modulate the reac-
tivity of microglia in early-deposing APP/PS1 mice. Of note, a
single i.p. injection of AZD 0530 in APP/PS1 mice was sufficient
to decrease Src activity in their brains (Figure S6E). Therefore,
and as we did for Rhoafl/fl:Cx3cr1CreER+ mice, we blocked Src
activity by giving AZD 0530 weekly to 3-month-old APP/PS1
mice for 1 month (Figure S6F) and investigated whether Src inhi-
bition would preserve hippocampal synapses. Injecting AZD
0530 in APP/PS1 mice substantially inhibited the decrease of
vGlut-1+/PSD-95+ synapses (Figure S6G). Concurrent with the
idea that Src inhibition decreases microglia activation, we found
increased microglial ramification in the neocortex of APP/PS1
mice injected with AZD 0530 (Figure S6H). Paralleling this
increased microglial ramification in APP/PS1 mice treated withFigure 5. Loss of Rhoa in Adult Microglia Produces an Amyloid-like Pa
(A) Confocal images of Ab deposits in Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ mice 5
100 mm.
(B) Western blot using M3.2 antibody (detecting APP and b-CTF) on lysates from
mice). GAPDH was the loading control.
(C) ELISA for Ab1-40 and Ab1-42 on neocortical extracts of RhoA
fl/fl and RhoAfl/fl:Cx
Ab1-42).
(D) Confocal images of methoxy-X04+ plaque-like deposits on RhoAfl/fl and RhoA
(E) Intracellular endogenous Ab42 (immunolabeled with anti-Ab42 clone 12F4) an
MCM overexpressing RhoaWT, RhoaT19N, or SrcY416F (n = 15–40 cells from 2 cu
solution for 20 min and in some conditions also treated with adalimumab (anti-T
(F) Flow cytometry showing expression of GTP-Rhoa, Csk, or Src pTyr416 inmicrog
3–4 mice).
(G) CHME3microglia expressing a RhoA FRET activity biosensor were recorded i
20 cells from 3 cultures).
(H) CHME3microglia expressing a Src FRET activity biosensor were mock transfe
and after treatment with 200 nM Ab1-42 oligomers (n = 15–16 cells from 3 culture
(I and J) CHME3microglia expressing a biosensor to measure NF-kB pathway act
23–25 from 3 cultures) or transfected with RhoAQ63L (n = 39 cells from 3 cultures) o
incubated with FcR blocker (20 min), followed by treatment with adalimumab (an
before (t = 0 min) and after treatment with 200 nM Ab1-42 oligomers.
Data are represented as mean with 95% CI. *p < 0.05 (unpaired t test in A–C and
12 Cell Reports 31, 107796, June 23, 2020AZD 0530, we also observed an increase in the ramification of
microglia following Src inhibition with AZD 0530 in
Rhoafl/fl:Cx3cr1CreER+ mice (Figure S6I).
Plaque-associated microglia restrict amyloid plaque forma-
tion, limiting pathology in AD mouse models by phagocytosis
of amyloid deposits (Wang et al., 2015). We thus investigated
whether Rhoa activation and consequent blockade of Src would
improvemicroglial engulfment of Ab. Chemogenetic activation of
Rhoa using the Rhoa-CID strategy significantly increased the up-
take of Ab1-42 by microglia (Figure 6A). Activation of Rhoa led to
Src inhibition, and accordingly, blockade of Src with AZD 0530
also increased Ab1-42 uptake by microglia (Figure 6B). Blocking
Src with AZD 0530 significantly increased microglia engulfment
of Ab deposits in brains of both APP/PS1 (Figure S6J) and
Rhoafl/fl:Cx3cr1CreER+ mice (Figures 6C and S6K). AZD 0530
treatment caused no significant alterations in the amounts of
APP either in APP/PS1 or in Rhoafl/fl:Cx3cr1CreER+ mice (Figures
S6L and S6M), indicating that AZD 0530 does not impact APP
production.
Paralleling the increased Ab clearance by microglia, we
observed a significant decrease of amyloid burden (Ab amounts
detected using BAM-10 and E610 antibodies) in the brain
of APP/PS1 mice injected with AZD 0530 (Figures S6N and
S6O). AZD 0530 also decreased Ab deposition (Figures 6D and
S6P), the production of both Ab1-40 and Ab1-42 peptides (Fig-
ure 6E), and the formation of fibrillar plaque-like structures
labeled by methoxy-X04 (Figure 6F) in the neocortex of
Rhoafl/fl:Cx3cr1CreER+ mice, indicating that blockade of Src
downstream of Rhoa mitigates amyloid burden.DISCUSSION
Crossing Cx3cr1CreER-EYFP mice (Parkhurst et al., 2013) with Rhoa
floxed mice (Herzog et al., 2011; Jackson et al., 2011) allowed us
to study the role of Rhoa in adult brainmicroglia and circumvented
some limitations of previous studies that used overexpression of
Rhoa dominant mutants (Bianchi et al., 2011; Ohsawa et al.,thology
0 days post-TAM (n = 7 mice for BAM-10 and 10 mice for M3.2). Scale bars:
the brains of Rhoafl/fl and Rhoafl/fl:Cx3cr1CreER+ 50 days post-TAM (n = 6–14
3cr1CreER+ 50 days post-TAM (n = 12–15 mice for Ab1-40 and n = 10–11 mice for
fl/fl:Cx3cr1CreER+ neocortices 50 days post-TAM (n = 5 mice).
d CellMask dye (cyan) in primary hippocampal neurons incubated for 24 h with
ltures). Microglial cultures were pre-incubated with an FcR receptor blocking
NF; 5 mg/ml; 48 h). Scale bar: 20 mm.
lia (gated usingCD45midCD11b+) from 4-month-oldWT andAPP/PS1mice (n =
n saline before (t = 0 min) and after treatment with 200 nM Ab1-42 oligomers (n =
cted or transfected with RhoAQ63L and then recorded in saline before (t = 0min)
s).
ivation (I) or a glutamate release FRET biosensor (J) were mock transfected (n =
r incubated with AZD 0530 (200 nM; 1 h; n = 31–34 cells from 3 cultures) or pre-
ti-TNF; 5 mg/ml; 48 h; n = 8 cells from 2 cultures), and then recorded in saline
F; one-way ANOVA in E; two-way ANOVA in G–J). See also Figure S6.
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C D
E
F
Figure 6. Src Inhibition Mitigates the Amyloid-like Pathology Elicited by the Loss of Rhoa in Adult Microglia
(A) CHME3 microglia were co-transfected with YFP-FKBP and Lyn11-FRB or with YFP-FKBP-Rhoa (CA) and Lyn11-FRB (n = 211–395 cells from 3 cultures). All
cells were treated with Ab1-42 fluorescent particles (10 mg/ml) and rapamycin (500 nM) for 90 min.
(B) CHME3 microglia (stained with CellMask dye; green) were treated with or AZD 0530 (n = 89–113 cells from 3 cultures) and incubated with Ab1-42 fluorescent
particles (10 mg/ml) for 90 min.
(C) Confocal images showing colocalization (white) of Iba1+ microglia with M3.2 immunoreactive amyloid deposits on tissue sections from Rhoafl/fl:Cx3cr1CreER+
mice (hippocampus) injected with 10 mg/kg AZD 0530 or DMSO (n = 8 mice). Scale bars: 10 mm.
(D) Confocal images showing M3.2+ amyloid deposits on tissue sections from Rhoafl/fl:Cx3cr1CreER+ mice injected with 10 mg/kg AZD 0530 or DMSO (n = 10
animals mice). Scale bars: 200 mm.
(E) ELISA for Ab1-40 and Ab1-42 on neocortical extracts of RhoA
fl/fl:Cx3cr1CreER+ mice injected with 10 mg/kg AZD 0530 or DMSO (n = 8–21 animals for Ab1-40 and
n = 8–14 animals for Ab1-42).
(F) Confocal images of methoxy-X04+ plaque-like deposits on neocortices RhoAfl/fl:Cx3cr1CreER+ mice injected with 10 mg/kg AZD 0530 or DMSO (n = 5 mice).
Scale bar: 50 mm.
Data are represented as mean with 95% CI. *p < 0.05 (Mann-Whitney test in A–D and F; unpaired t test in E). See also Figure S6.
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OPEN ACCESS2000; Moon et al., 2013), which may trigger off-target and trans-
dominant effects (Zhou and Zheng, 2013; Wang and Zheng,
2007), as well as the use of C3 exoenzyme toxin (Rattan et al.,
2003; Hoffmann et al., 2008), which inhibits not only Rhoa but
also Rhob and Rhoc (Mohr et al., 1992; Chardin et al., 1989).Rhoa works through multiple downstream pathways and ef-
fectors, and it is to be expected that the loss of Rhoa might
disturb the functions and/or interactions of more than one of its
effectors. For example, knocking out Rhoa in the mouse spinal
cord neuroepithelium does not cause cytokinesis defectsCell Reports 31, 107796, June 23, 2020 13
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OPEN ACCESS(Herzog et al., 2011), whereas knocking out the Rhoa effector
citron-kinase impairs cytokinesis (Di Cunto et al., 2000). This
could also explain why Rhoa deficiency activates microglia,
whereas the pharmacological inhibition of the Rhoa effector
Rho-kinase (ROCK) does not (Mueller et al., 2005; Chen et al.,
2013). Another factor potentially contributing to the disparity of
these 2 phenotypes is that, in addition of being activated by
Rhoa, ROCK can also be regulated by Rhoe/Rnd3 (Riento
et al., 2003) or by Rhoc (Riento and Ridley, 2003). Our data, how-
ever, suggested that Rhoc did not play a significant role in micro-
glia proinflammatory activation and microglia-induced
neurotoxicity.
ROCK inhibition by Y27632 or fasudil attenuates microglia
activation, promoting some functional recovery in animal models
for different neurological conditions (Mueller et al., 2005; Chen
et al., 2013; Chong et al., 2017, Sellers et al., 2018). Because
Rhoa is likely to exert its control over microglia immune activity
through several other downstream effectors besides ROCK, for
which activation can also be regulated independently of Rhoa
(Julian and Olson, 2014), these studies are not very informative
concerning Rhoa regulation of microglial function. In addition,
Y27632 and fasudil are not cell specific and have substantial
off-target effects (Vigil and Der, 2013), making it difficult to attri-
bute any phenotype solely to the inhibition of ROCK downstream
of Rhoa.
Excessive secretion of glutamate by microglia can induce ex-
citotoxic neuronal damage (Maezawa and Jin, 2010; Takeuchi
et al., 2006) and, by exacerbating neuronal activity, can also in-
crease the production of Ab species by neurons (Lesne´ et al.,
2005). Blocking TNF, and the consequent release of glutamate,
from microglia lacking Rhoa prevented neurite damage and
also the increase of Ab42 in primary hippocampal neurons. In-
jecting POM (a brain penetrant immunomodulatory agent that
also inhibits TNF expression) in Rhoa mutant mice decreased
brain TNF expression and attenuated synapse loss. Although
POM might have inhibited other pathways in addition to TNF,
our in vitro data demonstrated that TNF signaling was required
for neurite beading and synapse loss, suggesting that TNF
contributed to the synapse loss following Rhoa ablation in
microglia.
AZD0530 inhibits SFKphosphorylation, including Fyn, Src, Lyn,
and other family members. Although AZD 0530 inhibits Src more
potently than other SFK (for example the reported IC50 for Src is
2.7 nM, whereas that for Fyn is around 10 nM; Green et al.,
2009), and despite of our compelling in vitro results pointing out
a key and rather specific role of Src in driving the phenotype pro-
duced by depleting Rhoa in microglia, we cannot claim that,
in vivo, the only kinase inhibited was Src. This is also applicable
to the work of Kaufman et al. (2015), who report that the effect
of AZD 0530 in diminishing some aspects of AD-like pathology
in APP/PS1 mice is due to decreased Fyn activation in neurons.
It is likely that besides inhibiting Fyn in neurons, AZD 0530 might
also inhibit other SFKs in neurons and in other brain cell types,
including Src in microglia. Accordingly, and in the context of our
work, we cannot therefore exclude that the effect of AZD 0530
in preventing synapse loss and decreasing the amyloid burden
in Rhoa mutants and in APP/PS1 mice was contributed, at least
in part, by SFK inhibition in both glia and neurons.14 Cell Reports 31, 107796, June 23, 2020The dose-response curve of AZD 0530 revealed an apparent
IC50 of 0.024 mg/kg for Src inhibition in the brain. AZD 0530
has a half-life of 16 h in the brain (Kaufman et al., 2015); therefore,
around 0.0146 mg/kg (10.5 half-lives) of AZD 0530 will remain in
the brain following our administration protocol. Because the
lowest dose of AZD 0530 (0.002 mg/kg) we tested produced
around 30% of Src inhibition, these data show that the dosage
of AZD 0530 we used effectively sustained Src inhibition in the
brain, which is in accordance with a persistent effect of AZD
0530 reported for APP/PS1 mice after drug washout (Smith
et al., 2018).
We observed decreased Rhoa activity in microglia obtained
from early-depositing APP/PS1 mice, a stage in which synapse
loss was already present without robust amyloid pathology, sug-
gesting that such a decrease in Rhoa activation might have
contributed to the synapse loss in early-depositing APP/PS1
mice. Indeed, blocking Src, downstream of Rhoa, prevented
synapse loss, increased microglial engulfment of Ab, and
decreased Ab burden. However, substantial glial activation
driven by overexpressing proinflammatory cytokines can also
decrease amyloid burden in AD mice (Chakrabarty et al., 2010,
2011), casting doubts whether attenuating microglial activation
per se would be sufficient to preserve synapses as amyloid pa-
thology builds up during the course of AD.
Loss of synapses, LTP impairment, recognition memory defi-
cits, and deposition of Ab are consistent hallmarks found in hu-
man AD patients and in animal models of AD. Similarly, Rhoa
ablation in adult microglia reproduced some of these hallmarks,
further supporting the hypothesis that disrupting Rhoa signaling
produces spontaneous microglia activation, leading to neurode-
generation. In this regard, our data provide additional validation
to the notion of ‘‘microgliopathy’’ (Prinz and Priller, 2014), in
which microglia dysfunction, by itself, could initiate or be a major
cause of neurological disease.STAR+METHODS
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RhoA (67B9) antibody Cell Signaling Technology Cat#2117; RRID:AB_10693922
Active RhoA-GTP antibody NewEast Biosciences Cat#26904; RRID:AB_1961799
Src antibody [EPR5496] Abcam Cat#ab109381; RRID:AB_10865528
Amyloid beta precursor protein
antibody [Y188]
Abcam Cat#ab32136; RRID:AB_2289606
GFP antibody Abcam Cat#ab6673; RRID:AB_305643
Anti-NeuN antibody Millipore Cat#MAB377; RRID:AB_2298772
Phospho-Src Family (Tyr416) (D49G4)
Rabbit mAb antibody
Cell Signaling Technology Cat#6943; RRID:AB_10013641
Phospho-Src Family (Tyr416) Antibody Cell Signaling Technology Cat#2101; RRID:AB_331697
NF- kB p65 (L8F6) Mouse mAb antibody Cell Signaling Technology Cat#6956; RRID:AB_10828935
Csk (C74C1) Rabbit mAb antibody Cell Signaling Technology Cat#498; RRID:AB_2276592
Rabbit Anti-PSD95 Monoclonal Antibody,
Unconjugated, Clone D74D3
Cell Signaling Technology Cat#3409; RRID:AB_1264242
PSD95 Monoclonal Antibody (6G6-1C9) Thermo Fisher Scientific Cat#MA1-045; RRID:AB_325399
Anti Iba1, Rabbit antibody Wako Cat#019-19741; RRID:AB_839504
Mouse Anti-Glyceraldehyde-3-Phosphate
Dehydrogenase (GAPDH) Antibody,
Unconjugated
Hytest Cat#5G4-9B3; RRID:AB_1616725
Mouse Anti-beta-Actin Monoclonal
Antibody, Unconjugated, Clone AC-74
Sigma-Aldrich Cat#A2228; RRID:AB_476697
Monoclonal Anti-Synaptophysin antibody
produced in mouse
Sigma-Aldrich Cat#S5768; RRID:AB_477523
Mouse Anti-beta-Amyloid Protein
Monoclonal Antibody, Unconjugated,
Clone BAM-10
Sigma-Aldrich Cat#A5213; RRID:AB_476742
VGLUT 1 (vesicular glutamate transporter 1,
BNPI, SLC17A7) antibody
Synaptic Systems Cat#135 303; RRID:AB_887875
Anti-Synapsin 1 antibody Synaptic Systems Cat#106 011C5; RRID:AB_993033
Purified anti-mouse/rat b-Amyloid, 1-16
antibody
BioLegend Cat#805707; RRID:AB_2734556
Purified anti-b-Amyloid, 1-16 antibody BioLegend Cat#803004; RRID:AB_2715854
Purified anti-b-Amyloid, 1-42 antibody BioLegend Cat#805509; RRID:AB_2783381
LAMP1, mAb (Ly1C6) antibody Enzo Life Sciences Cat#ADI-VAM-EN001; RRID:AB_10630197
Anti-Histone H3, CT, pan antibody Millipore Cat#07-690; RRID:AB_417398
PE anti-mouse CD45 antibody BioLegend Cat#103106; RRID:AB_312971
APC anti-mouse/human CD11b antibody BioLegend Cat#101212; RRID:AB_312795
Alexa Fluor 647 anti-mouse/human
CD11b antibody
BioLegend Cat#101218; RRID:AB_389327
PerCP/Cyanine5.5 anti-mouse Ly-6C
antibody
BioLegend Cat#128012;RRID:AB_1659241
Goat Anti-Mouse IgG (H+L) Antibody, Alexa
Fluor 568 Conjugated
Molecular Probes Cat#A-11004; RRID:AB_2534072
(Continued on next page)
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Goat Anti-Rabbit IgG (H+L) Antibody, Alexa
Fluor 568 Conjugated
Molecular Probes Cat#A-11011; RRID:AB_143157
Goat anti-Mouse IgG (H+L) Secondary
Antibody, Alexa Fluor 594 conjugate
Thermo Fisher Scientific Cat#A-11005; RRID:AB_2534073
Goat anti-Rabbit IgG (H+L) Secondary
Antibody, Alexa Fluor 594 conjugate
Thermo Fisher Scientific Cat#A-11012; RRID:AB_2534079
Goat anti-Mouse IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor
Plus 647
Thermo Fisher Scientific Cat#A32728; RRID:AB_2633277
Goat anti-Rabbit IgG (H+L) Cross-
Adsorbed Secondary Antibody, Alexa
Fluor 647
Thermo Fisher Scientific Cat#A-21244; RRID:AB_2535812
Peroxidase-AffiniPure Donkey Anti-Rabbit
IgG (H+L) (min X Bov,Ck,Gt,GP,Sy
Hms,Hrs,Hu,Ms,Rat,Shp Sr Prot) antibody
Jackson ImmunoResearch Labs Cat#711-035-152; RRID:AB_10015282
Peroxidase-AffiniPure Donkey Anti-Mouse
IgG (H+L) (min X Bov,Ck,Gt,GP,Sy
Hms,Hrs,Hu,Rb,Rat,Shp Sr Prot) antibody
Jackson ImmunoResearch Labs Cat#715-035-151; RRID:AB_2340771
Adalimumab Selleckchem Cat#A2010
CD11b MicroBeads, human and mouse Miltenyi Biotech Cat#130-049-601
PE/Cy7 Annexin V BioLegend Cat#640950
Ki-67 antibody Abcam Cat#ab15580; RRID:AB_443209
Monoclonal Anti-beta-Amyloid antibody
produced in mouse
Sigma-Aldrich Cat#A5213; RRID:AB_476742
PE/Cy7 anti-mouse/human
CD11b antibody
BioLegend Cat#101215; RRID:AB_312798
PE/Cy7 anti-mouse CD192 (CCR2)
Antibody
BioLegend Cat#150611; RRID:AB_2616983
Fc Receptor Blocking Solution BioLegend Cat#422302; RRID:AB_2818986
Bacterial and Virus Strains
Subcloning Efficiency DH5a
Competent Cells
Thermo Fisher Scientific Cat#18265017
Chemicals, Peptides, and Recombinant Proteins
Recombinant Murine GM-CSF Peprotech Cat#315-03
Recombinant Human TNF-a Peprotech Cat#300-01A
Recombinant Murine TNF-a Peprotech Cat#315-01A
Amyloid b Protein Fragment 1-42 Sigma-Aldrich Cat#A9810; CAS Number 107761-42-2
Beta - Amyloid (1 - 42), HiLyte Fluor 555 -
labeled, Human
AnaSpec, Inc Cat#AS-60480-01
Lipopolysaccharide (LPS) from
Escherichia coli 0111:B4
Sigma-Aldrich Cat#L2630; MDL number MFCD00164401
Src Inhibitor-1 Sigma-Aldrich Cat#S2075; CAS Number: 179248-59-0
Rapamycin Sigma-Aldrich Cat#R8781
18a-Glycyrrhetinic acid Sigma-Aldrich Cat#G8503; CAS Number 1449-05-4
Tamoxifen Sigma-Aldrich Cat#T5648; CAS Number 10540-29-1
Pomalidomide Selleckchem Cat#S1567; CAS Number 19171-19-8
Saracatinib (AZD0530) Selleckchem Cat#S1006; CAS Number 379231-04-6
Recombinant Murine M-CSF Peprotech Cat#315-02
Zombie Violet Fixable Viability Kit BioLegend Cat#423114
Methoxy-X04 Tocris Cat#4920; CAS Number 863918-78-9
(Continued on next page)
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Critical Commercial Assays
Amyloid beta 40 Mouse ELISA Kit Thermo Fisher Scientific Cat#KMB3481
Murine TNF-a Standard ABTS ELISA
Development Kit
Peprotech Cat#900-K54
Amyloid beta 42 Mouse ELISA Kit Thermo Fisher Scientific Cat#KMB3441
Pierce ECL Western Blotting Substrate Thermo Fisher Scientific Cat#32106
Thermo Scientific SuperSignal West Pico
Chemiluminescent Substrate
Thermo Fisher Scientific Cat#10481755
ABTS ELISA Buffer Kit Peprotech Cat#900-K00
Experimental Models: Cell Lines
CHME3 cell line (distributed as HMC3 cells) ATCC Cat#CRL-3304; RRID:CVCL_II76
N9 cell line Prof. Claudia Verderio, CNR Institute of
Neuroscience, Cellular and Molecular
Pharmacology, Milan, Italy
RRID:CVCL_0452
Experimental Models: Organisms/Strains
Mouse: Rhoafl/fl:Cx3cr1CreER+ This work N/A
Mouse: TNF knock out Prof. Rui Applelberg, Universtity of Porto N/A
Mouse: B6;C3-Tg(APP695)3Dbo
Tg(PSEN1)5Dbo/Mmjax (herein APP/PS1)
The Jackson Laboratory RRID:MMRRC_041848-JAX
Mouse: B6.129P2(Cg)-Cx3cr1tm2.1(cre/ERT2)
Litt/WganJ (herein Cx3cr1CreER-EYFP)
The Jackson Laboratory Cat#JAX:021160; RRID:IMSR_JAX:021160
Mouse: Rhoatm1Jrel (herein Rhoafl/fl) MGI MGI:4950374
Oligonucleotides
Primers See Table S1 N/A
Oligos for pSicoR cloning See Table S1 N/A
shRNA oligos See Table S1 N/A
Recombinant DNA
pTriEx-RhoA FLARE.sc Biosensor Q63L PMID:16547516 RRID:Addgene_12151
pRK5-myc-RhoA-Q63L Gary Bokoch (unpublished) RRID:Addgene_12964
pRK5-myc-RhoA-T19N Gary Bokoch (unpublished) RRID:Addgene_12963
pRK5-myc-RhoA-wt Gary Bokoch (unpublished) RRID:Addgene_12962
pUSE-RapR-Src-myc PMID:20581846 RRID:Addgene_25933
pDisplay FLIPE-600n PMID:15939876 RRID:Addgene_13545
pIkBa-miRFP703 PMID:27539380 RRID:Addgene_80005
psPAX2 Didier Trono (unpublished) RRID:Addgene_12260
pMD2.G Didier Trono (unpublished) RRID:Addgene_12259
pUMVC PMID:12649500 RRID:Addgene_8449
GFP-RelA PMID:11533489 RRID:Addgene_23255
MSCV PMID:20008935 RRID:Addgene_24828
pSicoR PMID:15240889 RRID:Addgene_11579
YF-RhoA(CA) PMID:15908919 RRID:Addgene_20153
YFP-FKBP (YF) PMID:15908919 RRID:Addgene_20175
Lyn11-targeted FRB (LDR) PMID:15908919 RRID:Addgene_20147
pCherry-FRB PMID:20581846 RRID:Addgene_25920
mCherry-Lifeact-7 Michael Davidson (unpublished) RRID:Addgene_54491
RhoC FLARE.sc mCer, mVenus - wt PMID:24224016 RRID:Addgene_65071
Kras-Src FRET biosensor PMID:18799748 RRID:Addgene_78302
Raichu-RhoA Michiyuki Matsuda; PMID:12860967 N/A
pLNCX chick src Y416F Joan Brugge (unpublished) RRID:Addgene_13662
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pLNCX chick src Y527F Joan Brugge (unpublished) RRID:Addgene_13660
pLNCX chick src Joan Brugge (unpublished) RRID:Addgene_13665
pTriEx-RhoA FLARE.sc Biosensor WT PMID:16547516 RRID:Addgene_12150
pTriEx-RhoA FLARE.sc Biosensor T19N PMID:16547516 RRID:Addgene_12152
pFRET-HSP33 cys Ulrich Hammerling (unpublished) RRID:Addgene_16076
Software and Algorithms
Fiji PMID:22743772 RRID:SCR_002285
GraphPad Prism https://www.graphpad.com/ RRID:SCR_002798
Adobe Illustrator https://www.adobe.com/products/
illustrator.html
RRID:SCR_010279
Sholl analysis plugin for ImageJ PMID:25264773 (distributed with Fiji;
https://imagej.net/Downloads)
N/A
FlowJo https://www.flowjo.com/solutions/flowjo RRID:SCR_008520
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jo~ao
Relvas (jrelvas@ibmc.up.pt).
Materials Availability
This study did not generate new unique reagents.
Data and Code Availability
This study did not generate any unique codes.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All mice experiments were reviewed by i3S animal ethical committee and were approved by Direc¸~ao-Geral de Alimentac¸~ao e Veter-
ina´ria (DGAV). Animals were maintained in standard laboratory conditions with inverted 12h/12h light dark cycle and were allowed
free access to food and water. Animals were group-housed under specific pathogen-free conditions. Experiments were carried
out in adult mice (2-3 months of age) following the 3Rs ethics.
Conditional Rhoa-deficient mice
All mice experiments were approved by Direc¸~ao-Geral de Alimentac¸~ao e Veterina´ria (DGAV). Cx3cr1CreER-EYFP mice were purchased
from Jackson Laboratories. In such mice, the Cx3cr1 promoter drives high expression of the CreER cassette in microglia (Parkhurst
et al., 2013). Mice homozygous for the Rhoa floxed allele (Herzog et al., 2011; Jackson et al., 2011) were backcrossed at least for 10
generations and were kept in C57BL/6 background at the I3S animal facility. All genotypes were determined by PCR on genomic
DNA. Primers used for Rhoa floxed alleles were: AGC CAG CCT CTT GAC CGA TTT A (forward); TGT GGG ATA CCG TTT GAG
CAT (reverse). Primers for CreER insertion were: AAG ACT CAC GTG GAC CTG CT (WT forward); AGG ATG TTG ACT TCC GAG
TG (WT reverse); CGG TTA TTC AAC TTG CAC CA (mutant reverse).
Rhoa floxed mice were crossed with Cx3cr1CreER-EYFP mice. Progeny of interest were: Control (Rhoafl/fl) and mutants
(Rhoafl/fl:Cx3cr1CreER+). Mice were given tamoxifen (10 mg per animal by oral gavage) at P26 and P28 and then analyzed at different
time points (specified on the figure legends). All experiments were performed on mice kept on a C57BL/6 background. For electro-
physiological recordings and in behavioral tests onlymale Rhoafl/fl, Cx3cr1CreER+ andRhoafl/fl:Cx3cr1CreER+ littermateswere used. No
differences in the mRNA expression levels of Rhoa were found in FACS-sorted microglia between the brains of Rhoafl/fl - and wild-
type mice after TAM administration. In addition, after TAM administration, Rhoafl/fl mice displayed no overt difference in the behav-
ioral performance on motor, anxiety-related and memory tests when compared to wild-type mice. Administration of AZD 0530 (used
at a final concentration of 10mg/kg via IP injections; 1 IP per week lasting 4 weeks) to Rhoafl/fl:Cx3cr1CreER+ and Rhoafl/fl mice started
1 week after the second TAM pulse. Administration of pomalidomide (used at a final concentration of 50mg/kg via IP injections; 3 IPs
per week lasting 4 weeks) to Rhoafl/fl:Cx3cr1CreER+ and Cx3cr1CreER+ mice started 1 week after the second TAM pulse.Cell Reports 31, 107796, June 23, 2020 e4
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Prof. Rui Applelberg (University of Porto) supplied C57BL/6.Tnf knockout (referred herein as Tnf KO) mice. Tnf KO mice were gen-
otyped by PCR using ATC CGC GAC GTG GAA CTG GCA GAA (forward) and CTG CCC GGA CTC CGC AAA GTC TAA (reverse)
primer pair. Tnf KO mice display a single band of 2 kb in the PCR gel. Mice were bred at i3S animal facility. Tnf KO animals were
bred to maintain maximal heterozygosity.
AD mice
The AbPPswe/PS1A246E (termed APP/PS1) AD mice model co-expresses a chimeric mouse-human amyloid-b protein precursor
(AbPP) bearing a human Ab domain with mutations (K595N and M596L) linked to Swedish familial AD pedigrees and human prese-
nilin-1 A246E mutation, with both transgenes under the control of the mouse prion protein promoter (Borchelt et al., 1997). This AD
mouse model displays age-dependent and region-specific amyloidosis, gliosis and associated hippocampal-dependent memory
deficits, resembling the AD pathology found in human patients (Borchelt et al., 1997). APP/PS1 mice were genotyped by PCR using
PSEN primers: AAT AGA GAA CGGCAGGAG CA (forward) and GCC ATG AGGGCA CTA ATC AT (reverse); APP primers: GAC TGA
CCACTCGACCAGGTTCTG (forward) and CTTGTA AGT TGGATT CTCATA TCCG (reverse); WT primers: CCTCTT TGTGAC TAT
GGTGAC TGA TGTCGG (forward) and GTGGAT AACCCC TCCCCCAGCCTAGACC (reverse). APP/PS1mice weremaintained in
SV129 background and were bred at the i3S animal facility. Administration of AZD 0530 (used at a final concentration of 20 mg/kg via
IP injections; 1 IP per week lasting 4 weeks) to APP/PS1 mice started when animals completed 3 months of age.
Primary cultures of hippocampal neurons
Hippocampi were dissected from embryonic day 18 Wistar rat embryos and dissociated using trypsin (0.25%, v/v). Neurons were
plated at a final density of 1 3 104 to 5 3 104 cells per dish and cultured in the presence of a glial feeder layer. Cells were cultured
in Neurobasal medium supplemented with B27 supplement (1:50, v/v), 25 mM glutamate, 0.5 mM glutamine, and gentamicin
(0.12 mg/ml). To prevent glial overgrowth, neuronal cultures were treated with 5 mM cytosine arabinoside after 3 days in vitro
(DIV) and maintained in a humidified incubator with 5% CO2/95% air at 37
C for up to 2 weeks, feeding the cells once per week
by replacing one-third of the medium. To assess neurite beading, hippocampal neurons expressing mVenus were observed under
a fluorescence microscope after 24 h of incubation with 50% (v/v) microglia conditioned media. Neurons were observed blindly in
three independent hippocampal cultures. The ratio of bead-bearing mVenus+ neurons was calculated over the total mVenus+ neu-
rons counted.
Primary cultures of cortical microglia
Primary cortical microglial cell cultures were performed as previously described (Socodato et al., 2015a, 2015b; Portugal et al., 2017).
In brief, mice pups (2-day-old) were sacrificed, their cerebral cortices were dissected in HBSS, pH 7.2, and digested with 0.07%
trypsin plus 50 mL (w/v) DNase for 15 min. Next, cells were gently dissociated using a glass pipette in DMEM F12 GlutaMAX-I sup-
plemented with 10% FBS, 0.1% gentamicin. Cells were plated in poly-D-lysine-coated T-flasks (75 cm2) at 1.5x106 cells per cm2.
Cultures were kept at 37C and 95% air/5% CO2 in a humidified incubator. Culture media was changed every 3 days up to
21 days. To obtain purified microglial cell cultures, culture flasks were subjected to orbital shaking at 200 rpm for 2 h. Next, culture
supernatant was collected to tubes, centrifuged at 453 g for 5 min at room temperature. The supernatant was discarded and the pel-
let, containing microglia, was re-suspended in culture medium, and cells were seeded in poly-D-lysine-coated 6 or 12-well culture
plates at 2.5x105 cells/cm2 with DMEM F12 GlutaMAX-I supplemented with 10% FBS, 0.1% gentamicin and 1 ng/ml M-CSF or 1 ng/
ml GM-CSF. Purified microglia were cultured for 5-8 days. Immunolabeling with CD11b showed a purity of 95%–99% for these
cultures.
Microglial cell lines
The microglial cell line N9 was obtained by immortalization of primary cultures from the ventral mesencephalon and cerebral cortex
from ED12-13 CD1 mouse embryos with the 3RV retrovirus carrying an activated v-myc oncogene (Righi et al., 1989). Cells were
cultured in RPMI 1640 supplemented with 5% FBS, 23.8mM sodium bicarbonate, 30mM D-Glucose, 100 U/mL penicillin and
100 mg/mL streptomycin, and were maintained at 37C, 95% air and 5% CO2 in a humidified incubator.
The microglial cell line CHME3 was obtained from primary cultures of human embryonic microglial cells by transfection with a
plasmid encoding for the large T antigen of SV40 (Janabi et al., 1995). These cells were cultivated with DMEM GlutaMAX-I supple-
mented with 10% FBS and 100 U/mL penicillin and 100 m/mL streptomycin, and were maintained at 37C, 95% air and 5% CO2 in a
humidified incubator.
For generation of microglial stable cell sub-clones, N9 or CHME3 cultures were infected with viral particles and allowed to grow for
additional 48h. Cultures were then selected using puromycin as before (Socodato et al., 2015b; Portugal et al., 2017). Stable cell sub-
clones carrying an empty vector (pLKO) or the insert of interest were validated by western blotting or by qRT-PCR.
Primary microglial cells, N9 and CHME3 microglial cell lines were transfected using jetPRIME (Polyplus Transfection) according
to the manufacturer‘s protocol.e5 Cell Reports 31, 107796, June 23, 2020
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Flow cytometry and cell sorting
For characterization of microglia and macrophages in the samples, the following markers were used: CD45-PE, CD11b-APC,
CD11b-Alexa Fluor 647, CCR2-PE/Cy7 and Ly6C-PerCP/Cy5.5. Microglial and macrophages were collected from the tissues (brain,
blood and spleen) of control and mutant mice using density gradient separation. In brief, mice were anesthetized and then perfused
with ice-cold PBS. For single cell suspensions, tissues were quickly dissected, placed on ice-cold RPMI and mechanically homog-
enized. Cell suspension was passed through a 100 mm cell strainer and centrifuged over a discontinuous 70%/30% Percoll gradient.
Cells on the interface were collected, pelleted, washed extensively and then counted in a Neubauer chamber using trypan blue
exclusion to estimate the number of live cells. Single cell suspensions (5 3 105 cells) were incubated with different mixes of FACS
antibodies for 30 min at 4C in the dark. Compensation settings were determined using spleen from both control and mutant. Cell
suspensionswere evaluated on a FACSCanto II analyzer (BD Immunocytometry Systems). For intracellular staining, cell suspensions
were run over Percoll gradient, washed and counted as above. Afterward, cells were seeded in a U bottom 96-well plate and incu-
bated with CD45-PE, CD11b-Alexa Fluor 647 or CD11b-PE/Cy7. After antibody washing, cells were fixed in 2% PFA for 30 min,
washed in PBS and permeabilized with permeabilization buffer (Life Technologies 00-8333-56). Intracellular antibody staining mix
was prepared in permeabilization buffer and incubated with the cells overnight at 4C in the dark. After washing in permeabilization
buffer, cells were incubated with Alexa Fluor 488 or 647 secondary antibody for 1 h at 25C in the dark. After that, cells were washed
twice in permeabilization buffer, washed twice in FACS staining buffer (2% BSA, 0.1% sodium azide in PBS) and analyzed in FACS
Canto II. Fluorescence minus one controls for Rhoa, GTP-Rhoa, Csk and phospho-Src were prepared in mixes with CD45-PE and
CD11b-Alexa Fluor 647 CD11b-PE/Cy7 plus secondary antibodies alone. Cell sorting was performed on a FACS ARIA cell sorter.
Data were analyzed by FlowJo X10 software (TreeStar).
MACS isolation of adult microglia
Micewere sacrificed in a CO2 chamber and the brains were removed. The right hemisphere wasmechanically dissociated in ice-cold
Dounce buffer (15mM HEPES; 0,5% Glucose; and DNase in PBS) by 6 strokes in a tissue potter. Then, the homogenate was passed
through a 70 mmcell strainer, centrifuged and cells were counted in a TC10 Automated Cell Counter fromBIO-RAD using Trypan Blue
to exclude dead cells. 43 107 cells were pelleted by centrifugation (9300 g; 1 min; 4C) and resuspended in 360 mL of MACS Buffer
(0.5% BSA; 2 mM EDTA in PBS) followed by incubation with 40 mL CD11b Microbeads (130-093-634 Miltenyi Biotec). CD11b+
fraction was selected using LS columns (130-042-401 Miltenyi Biotec) in a MACS separator (Miltenyi Biotec) according to the man-
ufacture’s instructions. Eluted CD11b enriched fraction was centrifuged (9300 g; 1 min; 4C), the pellet was lysed in RIPA-DTT buffer
and used for protein isolation.
Brain tissue preparation and immunofluorescence
After animal perfusion with ice-cold PBS (15 ml) and fixation by perfusion with 4% PFA, brains were post-fixed by immersion in 4%
PFA in PBS, pH 7.4 overnight. After that, brains were washed with PBS and then cryoprotected using sucrose gradient in a row (15
and 30%). After 24 h, brains were mounted in OCT embedding medium, frozen and cryosectioned in the CM3050S Cryostat (Leica
Biosystems). Coronal sections from brains (30 mm thickness between bregma positions 1.0 mm and 2.0 mm) were collected non-
sequentially on Superfrost ultra plus slides. Brain sections from control and from mutant mice encompassing identical stereological
regions were collected on the same glass slide. Slides were stored at 20C until processed for immunohistochemistry.
Frozen sections were defrosted by at least 1 h and hydrated with PBS for 15 min. Sections were permeabilized with 0.25% Triton
X-100 for 15 min, washed with PBS for 10 min and blocked (5% BSA, 5% FBS, 0.1% Triton X-100) for 1 h. Primary antibodies were
incubated in blocking solution in a humidified chamber overnight at 4C. Secondary antibodies were incubated for 2 h in blocking
solution. After the secondary antibody, sections were washed three times for 10 min with PBS and incubated for 10 min with
DAPI and rinsed twice in PBS. Slides were coverslipped using glycergel or Immumount and visualized under a Leica TCS SP5 II
confocal microscope.
Image reconstruction and morphometric analysis
Images from tissue sections were acquired using a Leica HC PL APO Lbl. Blue 20x /0.70 IMM/CORR or a Leica HC PL APO CS 40x
/1.10 CORR water objective in 8-bit sequential mode using standard TCS mode at 400 Hz and the pinhole was kept at 1 airy in the
Leica TCS SP5 II confocal microscope. Images were resolved at 1024 3 1024 pixels format illuminated with 2%–5% DPSS561
561 nmwave laser using aHyD detector in the BrightRmode and entire Z series were acquired frommouse brain sections. Equivalent
stereological regions were acquired for all tissue sections within a given slide. Image series were deconvolved using the Hyugens
Professional using the Classic Maximum Likelihood Estimation (CMLE) algorithm together with a determined theoretical PSF estab-
lished using a routine-based implementation for the Hyugens software. Reconstruction and generation of 3D volumes of decon-
volved images were performed using the ImageJ 3D viewer plugin and cell counts were performed blinded on integral 3D
volume-rendered images. Sholl analyses were performed using an ImageJ Sholl plugin (Ferreira et al., 2014).
All immunostaining in sets of slides were performed together, using the same batch of primary and secondary antibodies, and
blocking and washing solutions. Furthermore, images from different sections within a given slide were acquired on the same day,Cell Reports 31, 107796, June 23, 2020 e6
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line potency; same objective; same fluorescence exposure times and offset for a given fluorophore; same camera binning, zoom and
ROI magnification; same pinhole aperture; same pixel size; same line averaging; same TCS scanner mode and speed; same z stack
step size and optical sectioning).
NeuN quantification
Number of NeuN+ neurons were manually scored from stereological identical images (3D volume-rendered) of the CA1 region of the
hippocampus of stained sections (6 images per hippocampal section; 6 hippocampal sections per animal).
Quantification of amyloid deposits
Briefly, M3.2, BAM-10 or 6E10 immunostained sections covering layers II/III and IV of the neocortex or CA1 region of the hippocam-
pus (4 images per section; 6 sections (BAM-10 and 6E10) or 10 sections (M3.2) per animal) were imaged, converted into 8-bit gray
scale, 3D volume-rendered and thresholded to highlight immunostained amyloid deposits. Using FIJI software, the percent of immu-
nostained area was calculated for each field and each section.
APP quantification
Briefly, APP immunostained sections covering layers II/III and IV of the neocortex (4 images per section; 6 sections per animal) were
imaged, converted into 16-bit gray scale, and thresholded to highlight immunostained APP amounts. Using FIJI software, the percent
of immunostained area was calculated for each field and each section.
Methoxy-X04 quantification
Briefly, stained sections covering layers II/III and IV of the neocortex (5 images per section; 4 sections per animal) were imaged, con-
verted into 16-bit gray scale, and thresholded to highlight stained. Using FIJI software, the percent of stained area was calculated for
each field and each section.
Quantification of synapses
Images from stereological identical hippocampal CA1 regions from each experimental group (3 images per hippocampi; 4 hippocam-
pal sections per animal) were acquired using a Leica HCPL APOCS40x /1.10 CORRwater objective at 10243 1024 pixels resolution
with 8-bit bidirectional non-sequential scanner mode at 400 Hz and pinhole at 1 airy in the Leica TCS SP5 II confocal microscope. Z
stacks were converted to maximum projection images using LAS AF routine and the LAS AF colocalization plugin processed each
projection using subtracted background (25%–36% offset for both channels) and thresholded foreground (35%–45% offset for
vGlut-1 channel; 30%–40% offset for PSD-95 channel). Values corresponding to the positive area of vGlut-1/PSD-95 colocalization
puncta (synapses) and values for the overall image area for each image was extracted using the LAS AF colocalization plugin and
statistically evaluated in GraphPad Prism.
TUNEL assay
Slides were defrosted at room temperature for at least 1 h. After that, sections were hydrated in PBS and fixed with 4% PFA for
10 min. After washes with PBS, sections were blocked (10% NGS; 0,1% BSA and 1% Triton X-100) for 1 h and then equilibrated
in TdT buffer (30 mM Tris-HCl; 140 mM Sodium Cacodylate; 1 mM Cobalt chloride; pH 7.2) for 10 min at room temperature. To
perform the TUNEL reaction was performed using 1.6 mL of TUNEL Enzyme (11767305001; Roche); 1.2 mL of Biotin-16-dUTP
(11093070910; Roche) and 1.2 mL of 1mMdATP in 200 mL of TdT buffer. The reaction was performed at 37C for 90min. The reaction
was stopped by incubation with 2x SSC buffer for 10 min. After washes with PBS, Cy3-conjugated Streptavidin (1:200 in blocking
solution) and DAPI (2 ug/ml) were incubated for 1 h at room temperature. After PBSwashes, sections weremounted with fluoroshield
(Sigma-Aldrich). The number of TUNEL+ cells was manually scored from stereological identical images of the CA1 region of the hip-
pocampus of stained sections (4 images per hippocampal section; 8 hippocampal sections per animal).
Quantification of Iba1 colocalization with amyloid deposits
Images from stereological identical neocortical or hippocampal CA1 regions from each experimental group (4 images per section; 6
sections per animal) were acquired using a Leica HC PL APO CS 40x /1.10 CORR water objective at 1024 3 1024 pixels resolution
with 8-bit bidirectional scanner mode at 200 Hz in the Leica TCS SP5 II confocal microscope. Z stacks were converted to maximum
projection images using LAS AF routine and the LAS AF colocalization plugin processed each projection using subtracted back-
ground (45%–55% offset for both channels) and thresholded foreground (65% offset for BAM-10/M3.2 channel; 20%–35% offset
for Iba1 channel). Values corresponding to the positive area of colocalization puncta and values for the overall image area for
each image were extracted using the LAS AF colocalization plugin and statistically evaluated in GraphPad Prism.
Immunofluorescence on cultured microglia
Microglial cultures were cultivated in glass coverslips. Coverslips were fixed with 4% PFA, washed three times for 5 min in PBS, per-
meabilized with 0.1% Triton X-100 for 10 min, washed again and incubated for 1 h in blocking solution (5% BSA). Primary antibodiese7 Cell Reports 31, 107796, June 23, 2020
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for 10 min with PBS and incubated with secondary antibodies for 1 h in blocking solution. Next, coverslips were washed three times
for 10minwith PBS. After the last secondary antibody (when double-labeling was performed), the coverslips were incubated for 1min
with 1 mg/ml DAPI, and rinsed twice in PBS. Coverslips were mounted with Immumount, visualized in a Leica DMI6000B inverted
epifluorescence microscope using PlanApo 63X/1.3NA glycerol immersion objective. Images were acquired with 43 4 binning using
a digital CMOS camera (ORCA-Flash4.0 V2, Hamamatsu Photonics).
For quantification, images were exported as raw 16-bit tiff using the LAS AF software. Background was subtracted in FIJI using the
roller-ball ramp in between 35%–50% pixel radius. Images were segmented in FIJI using the local Otsu threshold. Thresholded im-
ages were converted to binary mask using the dark background function. Binary mask images were multiplied for their respective
original channel images using the image calculator plug-in to generate amasked 32-bit float images relative to each channel. Original
coordinate vectors were retrieved from the ROI manager and FIJI returned the mean fluorescent intensity in gray values contained
within any single microglia using the multi-measure function. Mean fluorescent intensity for each single microglia were exported and
statistically evaluated with the GraphPad Prism software.
Time-lapse video microscopy and FRET assays
For live cell imaging, microglia were plated on plastic-bottom culture dishes (m-Dish 35 mm, iBidi). Imaging was performed using a
Leica DMI6000B inverted microscope. The excitation light source was a mercury metal halide bulb integrated with an EL6000 light
attenuator. High-speed low vibration external filter wheels (equipped with CFP/YFP excitation and emission filters) were mounted on
the microscope (Fast Filter Wheels, Leica Microsystems). A 440-520nm dichroic mirror (CG1, Leica Microsystems) and a PlanApo
63X 1.3NA glycerol immersion objective were used for CFP and FRET images. Images were acquired with 2x2 binning using a digital
CMOS camera (ORCA-Flash4.0 V2, Hamamatsu Photonics). Shading illumination was online-corrected for CFP and FRET channels
using a shading correction routine implemented for the LASAF software. At each time-point, CFP and FRET imageswere sequentially
acquired using different filter combination (CFP excitation plus CFP emission (CFP channel), and CFP excitation plus YFP emission
(FRET channel), respectively).
Quantification of biosensors was performed as before (Portugal et al., 2017; Socodato et al., 2015a, 2015b, 2018). In brief, images
were exported as 16-bit tiff files and processed in FIJI software. Background was dynamically subtracted from all frames from both
channels. Segmentation was achieved on a pixel-by-pixel basis using a modification of the Phansalkar algorithm. After background
subtraction and thresholding, binary masks were generated for the CFP and FRET images. Original CFP and FRET images were
masked, registered and bleach-corrected. Ratiometric images (CFP/FRET for KRas Src YPet probe and FLIPE glutamate release
probe or FRET/CFP for Raichu-Rhoa and Flare.Rhoc sensors) were generated as 32-bit float-point tiff images. Values corresponding
to the mean gray values were generated using the multi calculation function in FIJI and exported as mentioned above. KRas Src and
glutamate (pDisplay FLIPE-600nSURFACE) biosensors have been previously used in microglia giving reliable FRET to donor signals
within the probe dynamic range (Socodato et al., 2015a, 2015b, 2018; Portugal et al., 2017).
For quantification of microglial protrusion velocity, HMC3 microglia expressing Lifeact-mCherry were incubated in DMEMwithout
phenol red plus 15mMHEPES and recorded (5min frames for 90min at 37C) using appropriate dichroics for red fluorescent protein.
Time-lapse images were exported as 16-bit tiff files and processed in FIJI software using the multi kymograph plugin. Protrusion ve-
locities from Lifeact kymograms were extracted using a routine macro from the multi kymograph package in ImageJ.
Preparation of lysates (tissue and cell cultures)
For ELISA, brains were removed, different brains areas were isolated, fast frozen on dry ice and stored at 80C. Cortices were de-
frosted and 400 ul of homogenization buffer (50 mM Tris-Base, 4 mM EDTA, 150 mMNaCl, 0.1% Triton X-100 and protease inhibitor
cocktail containing AEBSF (Sigma – P8340)). Samples were sonicated (10 pulses of 1 s at 60Hz) and centrifuged for 15 min at 2271 g
at 4C. The pellets were discarded and samples were centrifuged again at 13500 g for 5minutes at 4C. The supernatant was used for
ELISA and the total amount of protein were estimated using the Pierce BCA protein assay kit.
For all other applications, cell cultures or mice tissues were lysed using RIPA-DTT buffer (150 mM NaCl, 50 mM Tris, 5 mM EGTA,
1% Triton X-100, 0.5% DOC, 0.1% SDS) supplemented with complete-mini protease inhibitor cocktail tablets, 1 mM DTT and phos-
phatase inhibitor cocktail. Samples were sonicated (6 pulses of 1 s at 60Hz) and centrifuged at 16,000 g, 4C for 10 min. The super-
natants were collected and the protein concentration was determined by the Pierce BCA protein assay kit. All samples were dena-
tured with sample buffer (0.5M Tris-HCl pH 6.8, 30%glycerol, 10%SDS, 0.6MDTT, 0.02%bromophenol blue) at 95C for 5min and
stored at 20C until use.
Enzyme-linked immunosorbent assay (ELISA)
The concentration of Tnf, Ab1-40 and Ab1-42 were quantified by ELISA following the instructions provided by the manufacturer
(Peprotech, UK). Absorbance at 405 nm, with wavelength correction at 650 nm, was measured with a multimode microplate reader
(Synergy HT, Biotek, USA). Values corresponding to pg/ml were obtaining by extrapolating a standard concentration curve using re-
combinant Tnf.Cell Reports 31, 107796, June 23, 2020 e8
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Extracellular glutamate wasmeasured inmicroglia culture supernatant by the formation of NADH in a reaction catalyzed by glutamate
dehydrogenase essentially as elsewhere (Socodato et al., 2015b). Briefly, Tris–acetate (75 mM, pH 8.4) plus NAD and ADP were
added to culture supernatants and initial fluorescence arbitrary unit (FAUi) was quantified in a Luminometer. Glutamate dehydroge-
nase was added for 30 min to promote the formation of alpha-ketoglutarate and NADH. NADH fluorescence was also determined
(FAUf). Relative extracellular glutamate content was plotted as FAUf - FAUi.
Nuclear and cytosolic fractionation
Cultures were washed twice with PBS, and cells were scraped off culture dishes with lysis buffer [50 mM tris-HCl, 5 mM EDTA,
100 mM NaCl, 1 mM DTT, 100 mM phenylmethylsulfonyl fluoride, 200 mM Na3VO4, 1% Triton X-100, leupeptin (4 mg/ml)]. Lysates
were centrifuged (16,000 g for 10 min at 4C), the supernatant (cytosolic fraction) was collected, and the pellet (nuclear fraction) was
resuspended. All samples were denatured with sample buffer for 5min at 95Cand stored at20C. Both fractions were subjected to
SDS–polyacrylamide gel electrophoresis (SDS-PAGE). To confirm the efficacy of the separation assay, we used LAMP-1 (Enzo Life
Sciences) as a cytosolic fraction marker and histone H3 (Millipore) as a nuclear fraction marker.
Western blotting
Samples were separated in SDS-PAGE, transferred to PVDF membranes, which were incubated overnight with primary antibodies.
Membranes were washed in TBS-T buffer pH 7.6, incubated with peroxidase-conjugated secondary antibodies and developed using
an ECL chemiluminescence kit or an ECF fluorescence kit. Images were acquired in a Typhoon FLA 9000 system or ChemiDoc XRS
System (Bio-Rad) and quantified by FIJI software.
Electrophysiology
For electrophysiological recordings, acute hippocampal slices from P65-80 male control and Rhoa mutants mice were prepared. All
procedures were carried out according to the European Union Guidelines for Animal Care (European Union Council Directive 2010/
63/EU) and Portuguese law (DL 113/2013) with the approval of the Institutional Animal Care and Use Committee.
Animals were sacrificed by decapitation after cervical displacement and the brain was rapidly removed in order to isolate the hip-
pocampus. Hippocampi were dissected in ice-cold artificial cerebrospinal fluid (aCSF) containing: 124 mM NaCl, 3 mM KCl, 1.2 mM
NaH2PO4, 25 mM NaHCO3, 2 mM CaCl2, 1 mMMgSO4 and 10 mM glucose), which was continuously gassed with 95%O2/5% CO2.
Hippocampal slices were quickly cut perpendicularly to the long axis of the hippocampus (400 mm thick) with a McIlwain tissue
chopper and allowed to recover functionally and energetically for at least 1 h in a resting chamber filled with continuously oxygenated
aCSF, at room temperature (22–25C), before being set up for electrophysiological recordings.
For extracellular recordings of field Excitatory Post-Synaptic Potentials (fEPSP), slices were transferred to a recording chamber for
submerged slices (1mL capacity plus 5mL dead volume) andwere constantly superfused at a flow rate of 3ml/min with aCSF kept at
32C, gassed with 95% O2 – 5%CO2. Evoked fEPSP were recorded extracellularly using a microelectrode (4 to 8 M extracellularly
using feraCSF solution placed in the stratum radiatum of the CA1 area). fEPSP data were acquired using an Axoclamp-2B amplifier
(Axon Instrumnets, USA). fEPSPs were evoked by stimulation through a concentric electrode to the Schaffer collateral fibers. Each
individual stimulus consisted of a 0.1 ms rectangular pulse applied once every 20 s, except otherwise indicated. Averages of six
consecutive responses were continuously acquired, digitized with theWinLTP program (Anderson and Collingridge, 2001) and quan-
tified as the slope of the initial phase of the averaged fEPSPs. The stimulus intensity was adjusted at the beginning of the experiment
to obtain a fEPSP slope close to 1 mV/ms, which corresponded to about 50% of the maximal fEPSP slope.
q-burst stimulation was used to induce LTP because this pattern of stimulation is considered closer to what physiologically occurs
in the hippocampus during episodes of learning andmemory in living animals (Albensi et al., 2007). After obtaining a stable recording
of the fEPSP slope, a q-burst of stimuli, consisting of 1 train of 4 bursts (200 ms interburst interval), each burst being composed of 4
pulses delivered at 100 Hz [1 x (43 4)], was applied, and the stimulus paradigm was then resumed to pre-burst conditions up to the
end of the recording period (60 min after burst stimulation). LTP magnitude was quantified as % change in the average slope of the
fEPSP taken from 50-60min after LTP induction as comparedwith the average slope of the fEPSPmeasured during the 10min before
induction of LTP. fEPSPs were recorded under basal stimulation conditions (standard stimulus intensity and frequency) and stability
of fEPSP slope values guaranteed for more than 10 min before changing any protocol parameter. One or two slices per animal were
tested at each experimental day.
Behavioral tests
Testing procedures were conducted in the dark phase of the light/dark cycle. Onlymalemicewere used in behavioral analysis. Before
each session, mice were removed from their home cage in the colony room and brought into the adjacent testing rooms (illuminated
with 100 lux and attenuated noise). Behavioral tests were performed in 3 consecutive days in the following order: (1) elevated plus-
maze; (2) open field; (3) novel object recognition. All tests were video-recorded. In the elevated plus-maze and open-field tests move-
ment and location of mice were analyzed by an automated tracking system equipped with an infrared-sensitive camera (Smart Videoe9 Cell Reports 31, 107796, June 23, 2020
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ware (Noldus Information Technology, Wageningen, the Netherlands). All apparatus were thoroughly cleaned with neutral soap after
each test session.
Elevated plus-maze (EPM)
Themaze wasmade of opaque gray PVC consisting of four arms arranged in a plus-shaped format; two arms have surrounding walls
(closed arms, 37x6 cm x18 cm-high), while the two opposing arms have no walls (open arms, 37x6 cm). The apparatus is elevated by
50 cm above the ground. Mice were placed on the central platform facing an open arm and were allowed to explore the maze for
5 min. Open arms entries and time spent in open arms were obtained automatically (video tracking) and used to assess anxiety-
like behavior.
Open field (OF)
Mice were placed in the center of an OF apparatus (403 403 40 cm) and then allowed to move freely for 10 min. The distance trav-
eled, peripheral activity and center activity (locomotion in the central section of the OF) were obtained automatically (video tracking).
Novel object recognition (NOR)
The NOR test was performed as previously described (Leger et al., 2013). Briefly, the test apparatus consists of an open box and the
objects used are made of plastic, glass or metal in three different shapes: cubes, pyramids and cylinders. The test consists of three
phases. During habituation phase mice are allowed to explore the apparatus for 10 min (time used to perform OF test). The following
day, the acquisition/sample phase starts by placing eachmouse in the apparatus with two identical objects (familiar) for 10min. Then
the mouse goes back to its home cage. After 4 h (inter-trial interval, ITI), the retention/choice session is performed. In this phase, the
apparatus contains a novel object and a copy of the previous familiar object; animals are allowed to explore these objects for 3 min.
Exploration was defined as follows: mouse touched the object with its nose or the mouse’s nose was directed toward the object at a
distance shorter than 2 cm (Ennaceur et al., 2005). Circling or sitting on the object was not considered exploratory behavior.
Increased time spent exploring the novel object serves as the measure of recognition memory for the familiar object. Positive differ-
ence between the exploration time for novel and familiar objects and a discrimination index (DI) above 0.5 were used as indicators of
object recognition (Ennaceur et al., 2005). The discrimination index (DI) was calculated as index of memory function, DI = (time
exploring the novel object) / (total time spent exploring both objects) (Ennaceur et al., 2005).
Cloning of shRNAs into pSicoR-GFP vector
The cloning was performed as previous described (Ventura et al., 2004). Briefly, shRNA oligos (Rhoa sense: TGTCAAGC
ATTTCTGTCCTTCAAGAGAATTTGGACAGAAATGCTTGACTTTTTTC and antisense: CGAGAAAAAAGTCAAGCATTTCTGTC
CAAATTCTCTTGAAATTTGGACAG AAATGCTTGACA; Rhob sense: TCGACGTCATCCTTATGTGCTTTTCAAGAG AAAGCACAT
AAGGATGACGTCGTTTTTTC and antisense: TCGAGAAAAAACGACGT CTTATGTGCTTTCTCTTGAAAAGCACATAAGGATGAC
GTCGA; Rhoc sense: TACCTG AGGCAAGATGAGCATATTCAAGAGATATGCTCATCTTGCCTCAGGTTTTTTTC and antisense: GAG
AAAAAAACCTGAGGCAAGATGAGCATATCTCTTGAATATGCTCATCT TGCCTCAGGTA were annealed and cloned into HpaI-XhoI-
digested pSicoR using the T4 ligase. Oligos insertion into the vector was validated using PCR and confirmed by sequencing. A control
shRNA with no mammalian target (directed against DsRed2; referred to as scrambled) was used in experiments using the pSicoR as
before (Portugal et al., 2017).
Lentiviruses/Retroviruses production
This protocol was performed exactly as described elsewhere (Socodato et al., 2012; Mejı´a-Garcı´a et al., 2013). Low passage
HEK293T cells were seeded in 100mmculture dishes.When cultures reached80%confluence cells were co-transfected overnight
with viruses-producing plasmids using jetPRIME. Transfection ratios were as follows: 6 mg of shRNA plasmids to 3 mg of psPAX2 to
3 mg of VSVG (2:1:1) for lentiviruses production or 8 mg of VSVG (or SrcY416F or SrcY527F construct to 4 mg of pUMVC to 2 mg of VSVG
(4:2:1) for retroviruses production. The next day, normal growth media replaced transfection media and cells were cultivated for an
additional 48 h. Next, media with viral particles were collected, centrifuged at 906 g for 15 min at 4C, and the supernatant was
collected into new tubes and kept at 80C.
Total RNA extraction, cDNA synthesis and qRT-PCR
Total cerebral cortex RNA was extracted using the Direct-zolTM RNAMiniPrep kit according to the manufacturer’s instructions. RNA
from FACS-sorted microglia was harvested using the Quick-RNAMicroPrep kit. RNAs quality and concentration were all determined
using a NanoDrop ND-1000 Spectrophotometer. cDNA synthesis was performed using 100-500 ng of total RNA (DNase I treated)
with SuperScript III First-Strand Synthesis SuperMix.
qRT-PCR was carried out using iQ SYBR Green Supermix on an iQ5 multicolor real-time PCR detection system (Bio-Rad). The
efficiency was analyzed using a log-based standard curve. Expression of PCR transcripts between genotypes was calculated using
the 2-deltaCt method with Yhwaz serving as the internal control gene.Cell Reports 31, 107796, June 23, 2020 e10
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Human Ab1-42 peptide (Genscript) was dissolved to 2 mM in DMSO essentially as before (Silva et al., 2017). For oligomer formation,
Ab1-42 peptide was diluted to 100 mM inCa
2+-free HBSS and incubated for 24-48 h at 4C. Oligomers were used at final concentration
of 200 nM in microglial cultures.
Ab1-42 uptake assay
HMC3 microglial cells were seeded on 96-well plate (PerkinElmer) at 13 104 cells per well using an automated Multidrop dispenser
(Thermo Scientific) and incubated for 24 hours at 37C in 5%CO2. Then, cells were co-transfected with FKBP-YFP and FRB-Lyn and
or with Rhoa-YF (CA) and FRB-Lyn. For chemogenetic activation of Rhoa, cells were pre-treated with rapamycin (Sigma; 500 nM) for
15 min. Different non-transfected cultures were also pre-incubated with AZD 0530 (Src inhibitor; 500 nM) or vehicle (DMSO) for
15 min. Afterward, cells were incubated with 10 mg/ml Ab(1–42) HiLyteTM Fluor 555-labeled (Eurogentec) for 90 min at 37C in 5%
CO2. Cells were then thoroughly washed, fixed with 4% MP-paraformaldehyde (w/v), permeabilized with 0.1% (v/v) Triton X-100
(Sigma) for 30 min at room temperature and labeled with DAPI and HCS CellMask (Invitrogen).
Images of microglial cultures were acquired using IN Cell Analyzer 2000microscope (GE Healthcare) using a large chip CCD Cam-
era (binning 2X2) and a Nikon 20x/0.45 NA Plan Fluor objective. Images of Ab1-42, DAPI-stained nuclei, HCS CellMask and in some
conditions transfected (YFP+) cells were acquired using appropriate dichroics for TexasRed, DAPI, Cy5 and FITC channels,
respectively. For Ab1-42 signal quantification, the CellProfiler (3.1.8) software was used. For nuclei segmentation, a global threshold-
ing strategy was used followed by Otsu local thresholding. Clumped microglial nuclei were distinguished and individualized. After-
ward, microglial cells were segmented using the raw HCS CellMask image through a propagation algorithm based on the minimum
cross entropy thresholdingmethod applied to the HCSCellMask channel using segmented nuclei as start point and then spanning up
to the edges of the labeled microglial plasma membrane. The mean fluorescent intensity of Ab1–42 HiLyte
TM Fluor 555 in each micro-
glial cell was retrieved and plotted for statistical evaluation.
QUANTIFICATION AND STATISTICAL ANALYSIS
Graphs are displayed as dot plots showing full data dispersion with the mean and the 95% confidence interval of the mean. p < 0.05
was the cut-off for considering statistically significant difference between comparisons in sampled groups. Experimental units in bio-
logical replicates were evaluated a priori for Gaussian distribution using the D’Agostino & Pearson omnibus normality test. When
comparing only 2 experimental groups, the unpaired Student t test with equal variance assumption was used for data with normal
distribution, while the Mann-Whitney test was used for with non-parametric data. When comparing 3 or more groups, ordinary
One-way ANOVA followed by the Bonferroni’s multiple comparations test was used for data with normal distribution, and the Krus-
kal-Wallis test followed by Dunn‘s multiple comparations test was used for non-parametric data. When comparing 4 groups with 2
independent variables, Two-way ANOVA followed by the Bonferroni’s multiple comparations test was used. All imaging quantifica-
tions (cell cultures, FACS or mice tissue sections) were blind performed. All statistical analyses were carried out using the Graph Pad
Prism 7.0 software. Further statistical details are indicated in the figure legends.e11 Cell Reports 31, 107796, June 23, 2020
